[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGu6vzslq9LZAYZp4-QJQDcjuRtj8HPEA-wkHAEsrnHU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"University of Michigan Rogel Cancer Center",[4],314,false,57,2,22989,49,111,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Breast Cancer",32,{"name":18,"count":19},"Prostate Cancer",28,{"name":21,"count":22},"Pancreatic Cancer",12,{"name":24,"count":25},"Multiple Myeloma",11,{"name":27,"count":28},"Bladder Cancer",9,{"name":30,"count":31},"Head and Neck Cancer",7,{"name":33,"count":31},"Colorectal Cancer",{"name":35,"count":36},"Metastatic Breast Cancer",6,[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03787680","Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","2023-01-26","Olaparib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04140162","Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy","2024-05-02","Daratumumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04477200","Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","2025-01-06","Mycophenolate Mofetil",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04848337","Pembrolizumab and Lenvatinib in Advanced\u002FMetastatic Neuroendocrine Prostate Cancer","2025-01-08","Pembrolizumab",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03842696","Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","2025-07-30","Vorinostat",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05988918","Multicenter Trial of ESK981 in Patients With Select Solid Tumors","2026-02-21","ESK981",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04748042","Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","2026-05","Abiraterone",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05183126","Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer","2026-06","Paclitaxel",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT05996107","Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+\u002FHER2- Breast Cancer","Ribociclib",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT03781986","APG-115 in Salivary Gland Cancer Trial","2026-07","APG-115",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,257,370,432,472,516,543,570,612,730,864,934,974,1028,1078,1112,1138,1188,1220,1247,1278,1296,1314,1332,1350,1376,1401,1419,1437,1455,1473,1491,1509,1527,1545,1571,1589,1618,1636,1662,1752,1807,1832,1856,1884,1902,1920,1939,1967,1991,2028,2046,2064,2089,2143,2161,2179,2197,2215,2318,2364,2408,2444,2470,2502,2539,2566,2588,2614,2636,2658,2680,2713,2741,2763,2801,2827,2852,2885,2912,2944,2972,3009,3032,3055,3073,3096,3114,3139,3157,3180,3198,3216,3234,3262,3280,3298,3316,3334,3352,3375,3401,3419,3437,3455,3473,3496,3520,3538,3556,3574,3592,3616,3634,3652,3675,3693,3719,3737,3759,3777,3795,3816,3841,3859,3877,3900,3918,3936,3959,3977,4001,4019,4037,4060,4084,4102,4124,4146,4164,4187,4210,4228,4252,4270,4294,4317,4338,4363,4381,4404,4427,4445,4468,4491,4509,4532,4556,4574,4592,4618,4636,4658,4682,4707,4731,4754,4782,4800,4823,4841,4863,4888,4906,4924,4947,4969,4993,5011,5035,5053,5075,5099,5117,5135,5215,5262,5300,5347,5373,5399,5421,5453,5484,5510,5533,5559,5586,5604,5622,5646,5664,5682,5707],{"intervention":77,"totalTrials":96,"cells":97},13,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":224,"PHASE4":226,"NA":235},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":138,"soonestReadout":214},[105,119,132,142,153,163,174,187,198,209],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":36,"conditions":113,"interventions":115},"NCT00570531","Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma","TERMINATED",[90],"2010-10","2013-06","2007-06",[114],"Loco-regional Esophageal Cancer",[116,77,117,118],"Bevacizumab","Cisplatin","5-Fluorouracil",{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT03416153","Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer","COMPLETED",[90],"2023-05-05","2025-05-05","2018-05-21",91,[129],"Oropharynx Cancer",[131,77],"Carboplatin",{"nctId":133,"briefTitle":134,"status":108,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT00161278","Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling",[90],"2006-08","2004-12",1,[140],"Advanced Non-Small Cell Lung Cancer",[131,77],{"nctId":143,"briefTitle":144,"status":122,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT03829722","Radiotherapy, Carboplatin\u002FPaclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer",[90],"2024-06-11","2019-09-05",26,[150],"Oropharynx Squamous Cell Carcinoma",[152,131,77],"Nivolumab",{"nctId":154,"briefTitle":155,"status":122,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"conditions":160,"interventions":162},"NCT00230451","Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma",[90],"1999-12","2008-07","1997-11",[161],"Esophageal Cancer",[77,117,118],{"nctId":164,"briefTitle":165,"status":122,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT00136175","Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder",[90],"2005-12","2007-10","1999-11",68,[27],[77,131,173],"Gemcitabine",{"nctId":175,"briefTitle":176,"status":177,"phases":178,"primaryCompletion":179,"start":180,"enrollment":100,"conditions":181,"interventions":183},"NCT02013453","A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer","WITHDRAWN",[90],"2016-12","2013-12",[182],"Cancer of Head and Neck",[184,131,185,77,186],"Omeprazole","5FU","Pemetrexed",{"nctId":188,"briefTitle":189,"status":122,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":19,"conditions":194,"interventions":195},"NCT00151060","Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate",[90],"2004-11","2006-06","1998-12",[18],[196,197,77],"Estramustine","Etoposide",{"nctId":199,"briefTitle":200,"status":122,"phases":201,"primaryCompletion":202,"completion":168,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT00151034","Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer",[90],"2004-08","2000-09",33,[206],"Urologic Neoplasms",[208,77,131,173],"Trastuzumab",{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":223},"NCT07121595","Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","RECRUITING",[90],"2030-07-01","2025-07-17",50,[218,219,220,221,222],"Oral Cavity Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8",[131,117,77],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":138,"soonestReadout":76},[228],{"nctId":74,"briefTitle":75,"status":212,"phases":229,"primaryCompletion":76,"completion":76,"start":230,"enrollment":231,"conditions":232,"interventions":234},[92],"2022-03-28",22,[15,233,161],"Metastatic Gastric Cancer",[77,77],{"trials":236,"activeCount":100},[237,248],{"nctId":238,"briefTitle":239,"status":122,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":11,"conditions":244,"interventions":246},"NCT02492867","A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer",[93],"2021-11-28","2022-04-21","2016-01-14",[245],"Carcinoma, Non-Small-Cell Lung",[131,77,247],"Durvalumab",{"nctId":249,"briefTitle":250,"status":122,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT00580983","Optimized Intensity Modulated Irradiation for Head and Neck Cancer",[93],"2010-06","2003-08",90,[30],[77,131,117,118],{"intervention":57,"totalTrials":28,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":276,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[263],{"nctId":264,"briefTitle":265,"status":108,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":275},"NCT03286114","Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab",[89],"2020-10-22","2021-04-28","2017-12-21",16,[272,273,274],"Myelodysplastic Syndromes","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia",[57],{"trials":277,"activeCount":363,"soonestReadout":56},[278,288,299,308,318,329,341,350],{"nctId":279,"briefTitle":280,"status":212,"phases":281,"primaryCompletion":282,"completion":282,"start":283,"enrollment":16,"conditions":284,"interventions":286},"NCT06356155","Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer",[90],"2028-03","2025-07-22",[285],"Urothelial Carcinoma",[287,57],"Enfortumab vedotin",{"nctId":289,"briefTitle":290,"status":108,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT03559049","Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer",[89,90],"2025-05-01","2018-12-24",25,[296],"Stage IV Non-small Cell Lung Cancer",[57,186,131,298],"Rucaparib",{"nctId":300,"briefTitle":301,"status":108,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":36,"conditions":306,"interventions":307},"NCT03287050","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",[90],"2019-03-13","2020-11-10","2018-01-24",[285],[57],{"nctId":309,"briefTitle":310,"status":122,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT03240016","Abraxane With Anti-PD1\u002FPDL1 in Patients With Advanced Urothelial Cancer",[90],"2023-06-23","2018-02-08",36,[285],[57,317],"Abraxane",{"nctId":54,"briefTitle":55,"status":319,"phases":320,"primaryCompletion":56,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":327},"ACTIVE_NOT_RECRUITING",[90],"2027-04","2021-05-25",45,[325,326],"Prostate Cancer Metastatic","Neuroendocrine Tumors",[57,328],"Lenvatinib",{"nctId":330,"briefTitle":331,"status":212,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":231,"conditions":336,"interventions":340},"NCT06580054","Pembrolizumab for the Treatment of Locally Advanced and\u002For Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma",[90],"2028-03-01","2030-03-01","2025-03-05",[337,338,339],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",[57],{"nctId":342,"briefTitle":343,"status":122,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":204,"conditions":347,"interventions":349},"NCT03242915","Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents",[90],"2025-02-20","2017-10-03",[348],"Non-small Cell Lung Cancer",[57,131,186],{"nctId":351,"briefTitle":352,"status":212,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":361},"NCT05956041","Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed\u002FRefractory Cutaneous T-cell Lymphomas",[90],"2026-12","2027-12","2023-12-06",23,[359,360],"Cutaneous T Cell Lymphoma","Fungoides Mycosis Sezary Syndrome",[57,362],"Mogamulizumab",4,{"trials":365,"activeCount":100},[],{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"intervention":52,"totalTrials":371,"cells":372},3,{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":390,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":138,"soonestReadout":51},[377],{"nctId":49,"briefTitle":50,"status":319,"phases":378,"primaryCompletion":51,"completion":379,"start":380,"enrollment":170,"conditions":381,"interventions":388},[89],"2027-11-05","2020-08-05",[382,383,384,385,386,387],"Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Astrocytoma, Grade IV","Newly Diagnosed Glioblastoma","Newly Diagnosed Gliosarcoma","Newly Diagnosed Astrocytoma, Grade IV",[52,389,52,52],"Temozolomide",{"trials":391,"activeCount":138,"soonestReadout":61},[392,413],{"nctId":59,"briefTitle":60,"status":319,"phases":393,"primaryCompletion":61,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":409},[89,90],"2026-04-01","2020-02-04",43,[398,399,400,401,402,272,403,404,405,406,407,408],"Hematologic Diseases","Acute Leukemia in Remission","Chronic Myelogenous Leukemia - Chronic Phase","Chronic Myelogenous Leukemia, Accelerated Phase","Chronic Myelogenous Leukemia, Blastic Phase","Mantle Cell Lymphoma","Follicular Lymphoma","Diffuse Large B Cell Lymphoma","Non Hodgkin Lymphoma","Graft Vs Host Disease","Graft-versus-host-disease",[62,410,411,52,412],"Tacrolimus","Methotrexate","Cyclophosphamide",{"nctId":414,"briefTitle":415,"status":122,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT00763490","Trial Of Double Umbilical Cord Blood Transplantation",[90],"2013-03","2015-10","2008-12",20,[422],"Hematological Malignancies",[424,425,52],"Flu\u002FBu4 conditioning regimen","Graft versus Host Disease prevention",{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":100},[],{"trials":431,"activeCount":100},[],{"intervention":389,"totalTrials":371,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":442,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":138,"soonestReadout":51},[438],{"nctId":49,"briefTitle":50,"status":319,"phases":439,"primaryCompletion":51,"completion":379,"start":380,"enrollment":170,"conditions":440,"interventions":441},[89],[382,383,384,385,386,387],[52,389,52,52],{"trials":443,"activeCount":138,"soonestReadout":458},[444,454],{"nctId":445,"briefTitle":446,"status":122,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":148,"conditions":451,"interventions":453},"NCT02805179","A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma",[90],"2020-02-06","2020-11-18","2016-09-22",[452],"Glioma",[389],{"nctId":455,"briefTitle":456,"status":319,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT04574856","Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma",[90],"2026-11-19","2027-11-19","2020-11-04",30,[463],"Glioblastoma",[389,465],"Adjuvant temozolomide",{"trials":467,"activeCount":100},[],{"trials":469,"activeCount":100},[],{"trials":471,"activeCount":100},[],{"intervention":42,"totalTrials":371,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":510,"PHASE4":512,"NA":514},{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":9,"soonestReadout":41},[480,493,503],{"nctId":481,"briefTitle":482,"status":122,"phases":483,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":491},"NCT04076579","Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma",[90],"2023-01-30","2024-09-26","2020-03-17",29,[489,490],"Sarcoma","Sarcoma Metastatic",[42,492],"Trabectedin",{"nctId":69,"briefTitle":70,"status":319,"phases":494,"primaryCompletion":71,"completion":71,"start":495,"enrollment":496,"conditions":497,"interventions":500},[90],"2021-05-28",21,[18,498,499],"Castrate Sensitive Prostate Cancer","Oligometastatic Disease",[72,501,502,42],"Prednisone","Androgen Deprivation Therapy",{"nctId":39,"briefTitle":40,"status":319,"phases":504,"primaryCompletion":41,"completion":505,"start":506,"enrollment":11,"conditions":507,"interventions":508},[90],"2028-08","2019-10-31",[18],[42,509],"AZD6738",{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"intervention":412,"totalTrials":9,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":519,"activeCount":100},[],{"trials":521,"activeCount":100},[],{"trials":523,"activeCount":9,"soonestReadout":61},[524,528],{"nctId":59,"briefTitle":60,"status":319,"phases":525,"primaryCompletion":61,"completion":394,"start":395,"enrollment":396,"conditions":526,"interventions":527},[89,90],[398,399,400,401,402,272,403,404,405,406,407,408],[62,410,411,52,412],{"nctId":529,"briefTitle":530,"status":212,"phases":531,"primaryCompletion":354,"completion":354,"start":532,"enrollment":231,"conditions":533,"interventions":535},"NCT03099356","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",[90],"2017-04-27",[534],"Metastatic Thyroid Cancer",[412,536],"Sirolimus",{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"intervention":501,"totalTrials":9,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":9,"soonestReadout":71},[551,555],{"nctId":69,"briefTitle":70,"status":319,"phases":552,"primaryCompletion":71,"completion":71,"start":495,"enrollment":496,"conditions":553,"interventions":554},[90],[18,498,499],[72,501,502,42],{"nctId":556,"briefTitle":557,"status":212,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":420,"conditions":561,"interventions":563},"NCT05901519","A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma",[90],"2026-08","2024-02-16",[562],"Hepatocellular Carcinoma",[501],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"trials":569,"activeCount":100},[],{"intervention":571,"totalTrials":9,"cells":572},"Leuprolide",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":100},[],{"trials":578,"activeCount":9,"soonestReadout":583},[579,591],{"nctId":580,"briefTitle":581,"status":319,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT04194554","A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer",[89,90],"2027-05","2029-05","2020-11-06",102,[18],[589,571,590],"Niraparib","Abiraterone Acetate",{"nctId":592,"briefTitle":593,"status":212,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":604},"NCT07158021","Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial",[90],"2028-01-01","2026-01-22",75,[599,600,601,602,603],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma",[605,571],"Goserelin",{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"intervention":131,"totalTrials":613,"cells":614},17,{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":9,"soonestReadout":85},[621,630,639,643,647,651,655,659,669,679,691,700,704,708,712],{"nctId":622,"briefTitle":623,"status":122,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":487,"conditions":627,"interventions":628},"NCT00585689","Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer",[90],"2013-04","2007-12",[27],[629,131,173],"ABI-007",{"nctId":83,"briefTitle":84,"status":319,"phases":631,"primaryCompletion":85,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":638},[89,90],"2027-01","2019-10-28",41,[636,637],"Malignant Salivary Gland Cancer","Salivary Gland Cancer",[86,131],{"nctId":120,"briefTitle":121,"status":122,"phases":640,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":641,"interventions":642},[90],[129],[131,77],{"nctId":133,"briefTitle":134,"status":108,"phases":644,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":645,"interventions":646},[90],[140],[131,77],{"nctId":289,"briefTitle":290,"status":108,"phases":648,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":649,"interventions":650},[89,90],[296],[57,186,131,298],{"nctId":143,"briefTitle":144,"status":122,"phases":652,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":653,"interventions":654},[90],[150],[152,131,77],{"nctId":164,"briefTitle":165,"status":122,"phases":656,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":657,"interventions":658},[90],[27],[77,131,173],{"nctId":660,"briefTitle":661,"status":108,"phases":662,"primaryCompletion":663,"completion":168,"start":664,"conditions":665,"interventions":667},"NCT00148135","Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site",[90],"2006-04","2001-05",[666],"Carcinoma of Unknown Primary",[131,173,668],"Capecitabine",{"nctId":670,"briefTitle":671,"status":122,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":678},"NCT02031250","Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer",[90],"2023-02-22","2014-02",106,[677],"Squamous Cell Carcinoma of the Head and Neck",[117,131],{"nctId":680,"briefTitle":681,"status":122,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT01633541","Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer",[90],"2021-11-06","2012-03",55,[687],"Laryngeal Cancer",[689,690,117,131],"AT-101","Docetaxel",{"nctId":692,"briefTitle":693,"status":122,"phases":694,"primaryCompletion":695,"completion":486,"start":696,"enrollment":496,"conditions":697,"interventions":698},"NCT03194373","Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[90],"2019-02-01","2017-10-12",[677],[699,131],"Palbociclib",{"nctId":175,"briefTitle":176,"status":177,"phases":701,"primaryCompletion":179,"start":180,"enrollment":100,"conditions":702,"interventions":703},[90],[182],[184,131,185,77,186],{"nctId":199,"briefTitle":200,"status":122,"phases":705,"primaryCompletion":202,"completion":168,"start":203,"enrollment":204,"conditions":706,"interventions":707},[90],[206],[208,77,131,173],{"nctId":342,"briefTitle":343,"status":122,"phases":709,"primaryCompletion":345,"completion":345,"start":346,"enrollment":204,"conditions":710,"interventions":711},[90],[348],[57,131,186],{"nctId":210,"briefTitle":211,"status":212,"phases":713,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":714,"interventions":715},[90],[218,219,220,221,222],[131,117,77],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[722,726],{"nctId":238,"briefTitle":239,"status":122,"phases":723,"primaryCompletion":241,"completion":242,"start":243,"enrollment":11,"conditions":724,"interventions":725},[93],[245],[131,77,247],{"nctId":249,"briefTitle":250,"status":122,"phases":727,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":728,"interventions":729},[93],[30],[77,131,117,118],{"intervention":152,"totalTrials":25,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":762,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[736,747],{"nctId":737,"briefTitle":738,"status":108,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":36,"conditions":742,"interventions":744},"NCT04431635","Dose De-escalation Study of the PI3k Alpha\u002FDelta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed\u002FRefractory Indolent Lymphoma",[89],"2023-11-14","2020-06-15",[743],"Indolent Lymphoma",[745,152,746],"Copanlisib","Rituximab",{"nctId":748,"briefTitle":749,"status":122,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":754,"interventions":760},"NCT05169957","Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)",[89],"2023-06-13","2024-07-17","2022-08-09",[755,756,757,758,759],"Melanoma, Ocular","Melanoma, Cutaneous","Metastatic Melanoma","Melanoma, Mucosal","Liver Metastases",[761,152],"Ipilimumab",{"trials":763,"activeCount":138,"soonestReadout":804},[764,776,785,789,800,814,824,834,845],{"nctId":765,"briefTitle":766,"status":122,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT03785873","Phase Ib\u002FII Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer",[89,90],"2024-11-15","2019-05-22",34,[772],"Biliary Tract Cancer",[152,774,118,775],"Nanoliposomal-Irinotecan","Leucovorin",{"nctId":777,"briefTitle":778,"status":122,"phases":779,"primaryCompletion":780,"completion":781,"start":782,"enrollment":16,"conditions":783,"interventions":784},"NCT03639935","Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy",[90],"2023-02-07","2024-04-30","2019-03-28",[772],[298,152],{"nctId":143,"briefTitle":144,"status":122,"phases":786,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":787,"interventions":788},[90],[150],[152,131,77],{"nctId":790,"briefTitle":791,"status":122,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":96,"conditions":796,"interventions":798},"NCT02989714","Phase Ib\u002FII Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",[89,90],"2019-02-25","2020-06-23","2017-03-16",[797],"Renal Cell Carcinoma",[799,152],"Interleukin-2",{"nctId":801,"briefTitle":802,"status":212,"phases":803,"primaryCompletion":804,"completion":804,"start":805,"enrollment":685,"conditions":806,"interventions":813},"NCT06866262","Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial",[89,90],"2031-08-01","2025-08-15",[807,808,809,810,811,812],"Locally Advanced Clear Cell Renal Cell Carcinoma","Locally Advanced Sarcomatoid Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[761,152],{"nctId":815,"briefTitle":816,"status":108,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":823},"NCT03562507","Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma",[90],"2022-10-18","2019-04-11",8,[822],"Renal Cell Carcinoma, Metastatic",[67,152],{"nctId":825,"briefTitle":826,"status":122,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":597,"conditions":831,"interventions":833},"NCT03101566","Study of Nivolumab in Combination With Gemcitabine\u002FCisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer",[90],"2019-12-03","2021-06-07","2017-09-08",[832],"Biliary Tract Neoplasms",[173,117,761,152],{"nctId":835,"briefTitle":836,"status":122,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":363,"conditions":841,"interventions":843},"NCT03927105","Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed\u002FRefractory Peripheral T Cell Lymphoma",[90],"2019-11-01","2023-07-06","2019-04-25",[842],"Peripheral T Cell Lymphoma",[152,844],"cabiralizumab",{"nctId":846,"briefTitle":847,"status":122,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":857},"NCT03570619","Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations",[90],"2022-12-22","2024-03-26","2018-12-14",56,[854,855,856],"Metastatic Castration Resistant Prostate Cancer","Metastatic Cancer","Solid Tumor",[152,761],{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"intervention":410,"totalTrials":865,"cells":866},5,{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":138,"soonestReadout":61},[873,877,892,906,916],{"nctId":59,"briefTitle":60,"status":319,"phases":874,"primaryCompletion":61,"completion":394,"start":395,"enrollment":396,"conditions":875,"interventions":876},[89,90],[398,399,400,401,402,272,403,404,405,406,407,408],[62,410,411,52,412],{"nctId":878,"briefTitle":879,"status":122,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT00639717","Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant",[90],"2012-01","2016-04","2009-03",48,[886],"Graft Versus Host Disease",[888,889,890,891],"tacrolimus","mycophenolate","etanercept","methoxsalen",{"nctId":893,"briefTitle":894,"status":122,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":904},"NCT02145403","Phase 1\u002F2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies",[89,90],"2018-11-26","2020-10-16","2014-10",53,[901,902,903],"Hematologic Malignancies","Relapse","Graft-Versus-Host Disease",[905,410],"Carfilzomib",{"nctId":907,"briefTitle":908,"status":122,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":914},"NCT02328755","Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia",[89,90],"2019-03-25","2015-01",37,[273],[915,410,411],"peg-IFN-α",{"nctId":917,"briefTitle":918,"status":122,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":148,"conditions":923,"interventions":927},"NCT01790568","Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant",[90],"2017-01-01","2017-10-31","2014-12",[924,925,926],"Graft vs Host Disease","Hematologic Neoplasms","Non-Neoplastic Hematologic and Lymphocytic Disorder",[62,410,411],{"trials":929,"activeCount":100},[],{"trials":931,"activeCount":100},[],{"trials":933,"activeCount":100},[],{"intervention":761,"totalTrials":865,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":944,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[940],{"nctId":748,"briefTitle":749,"status":122,"phases":941,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":942,"interventions":943},[89],[755,756,757,758,759],[761,152],{"trials":945,"activeCount":138,"soonestReadout":804},[946,950,954,964],{"nctId":801,"briefTitle":802,"status":212,"phases":947,"primaryCompletion":804,"completion":804,"start":805,"enrollment":685,"conditions":948,"interventions":949},[89,90],[807,808,809,810,811,812],[761,152],{"nctId":825,"briefTitle":826,"status":122,"phases":951,"primaryCompletion":828,"completion":829,"start":830,"enrollment":597,"conditions":952,"interventions":953},[90],[832],[173,117,761,152],{"nctId":955,"briefTitle":956,"status":108,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":363,"conditions":961,"interventions":963},"NCT02097732","Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery",[90],"2016-08","2020-07","2014-04",[757,962],"Brain Metastases",[761],{"nctId":846,"briefTitle":847,"status":122,"phases":965,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":966,"interventions":967},[90],[854,855,856],[152,761],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"intervention":975,"totalTrials":363,"cells":976},"Bortezomib",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":992,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[981],{"nctId":982,"briefTitle":983,"status":122,"phases":984,"primaryCompletion":829,"completion":829,"start":985,"enrollment":986,"conditions":987,"interventions":990},"NCT02613598","Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma",[89],"2016-05-12",15,[988,989],"Hodgkin's Lymphoma","Lymphoma, Non-Hodgkin",[975,991],"Ruxolitinib",{"trials":993,"activeCount":138,"soonestReadout":46},[994,1003,1011],{"nctId":995,"briefTitle":996,"status":177,"phases":997,"primaryCompletion":998,"completion":999,"start":959,"enrollment":100,"conditions":1000,"interventions":1001},"NCT03617484","Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma",[90],"2023-01","2030-07",[403],[975,1002],"Ibrutinib",{"nctId":44,"briefTitle":45,"status":319,"phases":1004,"primaryCompletion":46,"completion":1005,"start":1006,"enrollment":8,"conditions":1007,"interventions":1008},[90],"2026-05-02","2020-10-05",[24],[47,1009,975,1010],"Lenalidomide","Dexamethasone",{"nctId":1012,"briefTitle":1013,"status":122,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1020},"NCT00724568","Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma",[89,90],"2009-04","2014-09-03","2008-05",74,[24],[1009,975,1010,1021],"Doxil",{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"trials":1027,"activeCount":100},[],{"intervention":991,"totalTrials":363,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1038,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1031,"activeCount":100},[],{"trials":1033,"activeCount":100},[1034],{"nctId":982,"briefTitle":983,"status":122,"phases":1035,"primaryCompletion":829,"completion":829,"start":985,"enrollment":986,"conditions":1036,"interventions":1037},[89],[988,989],[975,991],{"trials":1039,"activeCount":138,"soonestReadout":1044},[1040,1052,1062],{"nctId":1041,"briefTitle":1042,"status":212,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":76,"enrollment":420,"conditions":1046,"interventions":1050},"NCT06616155","Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[89,90],"2028-06","2030-06",[1047,1048,1049],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8",[1051,991],"Enzalutamide",{"nctId":1053,"briefTitle":1054,"status":122,"phases":1055,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":36,"conditions":1059,"interventions":1061},"NCT02400463","A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome",[90],"2019-10-10","2020-01-07","2016-02-05",[1060],"Hemophagocytic Syndrome (HPS)",[991],{"nctId":1063,"briefTitle":1064,"status":177,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":100,"conditions":1068,"interventions":1070},"NCT02973711","A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",[89,90],"2021-08","2018-01",[1069],"Leukemia, Chronic Myeloid",[1071,991],"Nilotinib",{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"intervention":62,"totalTrials":371,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1096,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[1084],{"nctId":1085,"briefTitle":1086,"status":108,"phases":1087,"primaryCompletion":1088,"completion":1089,"start":1090,"enrollment":22,"conditions":1091,"interventions":1093},"NCT00565227","Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.",[89],"2008-11","2009-09","2007-04",[1092,18,27,285],"Non-Small-Cell Lung Carcinoma",[1094,1095],"vorinostat","docetaxel",{"trials":1097,"activeCount":138,"soonestReadout":61},[1098,1102],{"nctId":59,"briefTitle":60,"status":319,"phases":1099,"primaryCompletion":61,"completion":394,"start":395,"enrollment":396,"conditions":1100,"interventions":1101},[89,90],[398,399,400,401,402,272,403,404,405,406,407,408],[62,410,411,52,412],{"nctId":917,"briefTitle":918,"status":122,"phases":1103,"primaryCompletion":920,"completion":921,"start":922,"enrollment":148,"conditions":1104,"interventions":1105},[90],[924,925,926],[62,410,411],{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"intervention":411,"totalTrials":371,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":138,"soonestReadout":61},[1120,1124,1128],{"nctId":59,"briefTitle":60,"status":319,"phases":1121,"primaryCompletion":61,"completion":394,"start":395,"enrollment":396,"conditions":1122,"interventions":1123},[89,90],[398,399,400,401,402,272,403,404,405,406,407,408],[62,410,411,52,412],{"nctId":907,"briefTitle":908,"status":122,"phases":1125,"primaryCompletion":910,"completion":910,"start":911,"enrollment":912,"conditions":1126,"interventions":1127},[89,90],[273],[915,410,411],{"nctId":917,"briefTitle":918,"status":122,"phases":1129,"primaryCompletion":920,"completion":921,"start":922,"enrollment":148,"conditions":1130,"interventions":1131},[90],[924,925,926],[62,410,411],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"intervention":1139,"totalTrials":371,"cells":1140},"Pacritinib",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1160,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[1145],{"nctId":1146,"briefTitle":1147,"status":108,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":363,"conditions":1152,"interventions":1159},"NCT03601819","Pacritinib in Relapsed\u002FRefractory Lymphoproliferative Disorders",[89],"2020-03-07","2020-07-17","2019-05-15",[1153,1154,1155,1156,1157,1158,403],"Lymphoma, T-Cell, Cutaneous","Lymphoma, T-Cell, Peripheral","Chronic Lymphocytic Leukemia","Lymphoproliferative Disorders","Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[1139],{"trials":1161,"activeCount":138,"soonestReadout":1175},[1162,1171],{"nctId":1163,"briefTitle":1164,"status":177,"phases":1165,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":100,"conditions":1168,"interventions":1170},"NCT02677948","Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)",[89,90],"2018-10","2016-10",[1155,1169],"Lymphoma, Small Lymphocytic",[1139,1002],{"nctId":1172,"briefTitle":1173,"status":212,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1181},"NCT04858256","Pacritinib in Relapsed\u002FRefractory T-cell Lymphoproliferative Neoplasms",[90],"2027-11","2028-11","2023-03-29",100,[1180,1156],"T-Cell Neoplasm",[1139],{"trials":1183,"activeCount":100},[],{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[],{"intervention":1009,"totalTrials":371,"cells":1189},{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1214,"PHASE4":1216,"NA":1218},{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":138,"soonestReadout":46},[1196,1200,1210],{"nctId":44,"briefTitle":45,"status":319,"phases":1197,"primaryCompletion":46,"completion":1005,"start":1006,"enrollment":8,"conditions":1198,"interventions":1199},[90],[24],[47,1009,975,1010],{"nctId":1201,"briefTitle":1202,"status":122,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":16,"conditions":1206,"interventions":1207},"NCT02331368","Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT\u002FASCT for Multiple Myeloma",[90],"2017-06","2015-06",[24],[1208,1009,1209],"Melphalan","MK-3475",{"nctId":1012,"briefTitle":1013,"status":122,"phases":1211,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1212,"interventions":1213},[89,90],[24],[1009,975,1010,1021],{"trials":1215,"activeCount":100},[],{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"intervention":1051,"totalTrials":9,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1235,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":100},[1226],{"nctId":1227,"briefTitle":1228,"status":108,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":28,"conditions":1232,"interventions":1233},"NCT03300505","ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer",[89],"2023-01-24","2019-05-31",[18],[1234,1051],"ARRx",{"trials":1236,"activeCount":138,"soonestReadout":1044},[1237],{"nctId":1041,"briefTitle":1042,"status":212,"phases":1238,"primaryCompletion":1044,"completion":1045,"start":76,"enrollment":420,"conditions":1239,"interventions":1240},[89,90],[1047,1048,1049],[1051,991],{"trials":1242,"activeCount":100},[],{"trials":1244,"activeCount":100},[],{"trials":1246,"activeCount":100},[],{"intervention":67,"totalTrials":9,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1250,"activeCount":100},[],{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":138,"soonestReadout":66},[1255,1268],{"nctId":64,"briefTitle":65,"status":319,"phases":1256,"primaryCompletion":66,"completion":1257,"start":1258,"enrollment":613,"conditions":1259,"interventions":1267},[90],"2027-08","2024-04-19",[1260,1261,1262,1263,1264,1265,1266],"Pancreatic Adenocarcinoma","Adenosquamous Carcinoma","Pancreatic Neuroendocrine Tumor","Pancreatic Neuroendocrine Carcinoma","Gastrointestinal Neuroendocrine Tumor","Gastrointestinal Neuroendocrine Carcinoma","Neuroendocrine Prostate Carcinoma",[67],{"nctId":815,"briefTitle":816,"status":108,"phases":1269,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":1270,"interventions":1271},[90],[822],[67,152],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"intervention":86,"totalTrials":138,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":100},[],{"trials":1283,"activeCount":100},[],{"trials":1285,"activeCount":138,"soonestReadout":85},[1286],{"nctId":83,"briefTitle":84,"status":319,"phases":1287,"primaryCompletion":85,"completion":632,"start":633,"enrollment":634,"conditions":1288,"interventions":1289},[89,90],[636,637],[86,131],{"trials":1291,"activeCount":100},[],{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":100},[],{"intervention":287,"totalTrials":138,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":138,"soonestReadout":282},[1304],{"nctId":279,"briefTitle":280,"status":212,"phases":1305,"primaryCompletion":282,"completion":282,"start":283,"enrollment":16,"conditions":1306,"interventions":1307},[90],[285],[287,57],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[],{"trials":1313,"activeCount":100},[],{"intervention":47,"totalTrials":138,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":100},[],{"trials":1321,"activeCount":138,"soonestReadout":46},[1322],{"nctId":44,"briefTitle":45,"status":319,"phases":1323,"primaryCompletion":46,"completion":1005,"start":1006,"enrollment":8,"conditions":1324,"interventions":1325},[90],[24],[47,1009,975,1010],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[],{"trials":1331,"activeCount":100},[],{"intervention":465,"totalTrials":138,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[],{"trials":1339,"activeCount":138,"soonestReadout":458},[1340],{"nctId":455,"briefTitle":456,"status":319,"phases":1341,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":1342,"interventions":1343},[90],[463],[389,465],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[],{"intervention":1351,"totalTrials":138,"cells":1352},"Starch, Potato",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":138,"soonestReadout":1363},[1359],{"nctId":1360,"briefTitle":1361,"status":212,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":420,"conditions":1366,"interventions":1369},"NCT07443943","A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial",[90],"2027-09","2028-04","2026-04-22",[1367,599,600,601,1368],"Anatomic Stage 0 Breast Cancer AJCC v8","Localized Breast Carcinoma",[1351],{"trials":1371,"activeCount":100},[],{"trials":1373,"activeCount":100},[],{"trials":1375,"activeCount":100},[],{"intervention":1377,"totalTrials":138,"cells":1378},"Platinum based chemotherapy",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":138,"soonestReadout":1389},[1385],{"nctId":1386,"briefTitle":1387,"status":319,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1394},"NCT06234748","Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer",[90],"2028-07","2023-12-20",19,[129,1393],"HPV-Related Carcinoma",[1377],{"trials":1396,"activeCount":100},[],{"trials":1398,"activeCount":100},[],{"trials":1400,"activeCount":100},[],{"intervention":536,"totalTrials":138,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":138,"soonestReadout":354},[1409],{"nctId":529,"briefTitle":530,"status":212,"phases":1410,"primaryCompletion":354,"completion":354,"start":532,"enrollment":231,"conditions":1411,"interventions":1412},[90],[534],[412,536],{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"intervention":72,"totalTrials":138,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":100},[],{"trials":1424,"activeCount":100},[],{"trials":1426,"activeCount":138,"soonestReadout":71},[1427],{"nctId":69,"briefTitle":70,"status":319,"phases":1428,"primaryCompletion":71,"completion":71,"start":495,"enrollment":496,"conditions":1429,"interventions":1430},[90],[18,498,499],[72,501,502,42],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"intervention":502,"totalTrials":138,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":138,"soonestReadout":71},[1445],{"nctId":69,"briefTitle":70,"status":319,"phases":1446,"primaryCompletion":71,"completion":71,"start":495,"enrollment":496,"conditions":1447,"interventions":1448},[90],[18,498,499],[72,501,502,42],{"trials":1450,"activeCount":100},[],{"trials":1452,"activeCount":100},[],{"trials":1454,"activeCount":100},[],{"intervention":589,"totalTrials":138,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":138,"soonestReadout":583},[1463],{"nctId":580,"briefTitle":581,"status":319,"phases":1464,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":1465,"interventions":1466},[89,90],[18],[589,571,590],{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"intervention":590,"totalTrials":138,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":138,"soonestReadout":583},[1481],{"nctId":580,"briefTitle":581,"status":319,"phases":1482,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":1483,"interventions":1484},[89,90],[18],[589,571,590],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":100},[],{"trials":1490,"activeCount":100},[],{"intervention":605,"totalTrials":138,"cells":1492},{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1494,"activeCount":100},[],{"trials":1496,"activeCount":100},[],{"trials":1498,"activeCount":138,"soonestReadout":595},[1499],{"nctId":592,"briefTitle":593,"status":212,"phases":1500,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":1501,"interventions":1502},[90],[599,600,601,602,603],[605,571],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"intervention":328,"totalTrials":138,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":138,"soonestReadout":56},[1517],{"nctId":54,"briefTitle":55,"status":319,"phases":1518,"primaryCompletion":56,"completion":321,"start":322,"enrollment":323,"conditions":1519,"interventions":1520},[90],[325,326],[57,328],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":100},[],{"intervention":509,"totalTrials":138,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":138,"soonestReadout":41},[1535],{"nctId":39,"briefTitle":40,"status":319,"phases":1536,"primaryCompletion":41,"completion":505,"start":506,"enrollment":11,"conditions":1537,"interventions":1538},[90],[18],[42,509],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"intervention":1546,"totalTrials":138,"cells":1547},"Iron chelation",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":138,"soonestReadout":1558},[1554],{"nctId":1555,"briefTitle":1556,"status":212,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":216,"conditions":1561,"interventions":1563},"NCT06784336","Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation",[90],"2028-10","2029-10","2025-10-15",[1562],"Allogeneic Stem Cell Transplant",[1546,1564],"Potato Resistant Starch",{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[],{"intervention":1564,"totalTrials":138,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"trials":1578,"activeCount":138,"soonestReadout":1558},[1579],{"nctId":1555,"briefTitle":1556,"status":212,"phases":1580,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":216,"conditions":1581,"interventions":1582},[90],[1562],[1546,1564],{"trials":1584,"activeCount":100},[],{"trials":1586,"activeCount":100},[],{"trials":1588,"activeCount":100},[],{"intervention":1590,"totalTrials":138,"cells":1591},"Ivonescimab",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":138,"soonestReadout":1602},[1598],{"nctId":1599,"briefTitle":1600,"status":212,"phases":1601,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":19,"conditions":1605,"interventions":1611},"NCT07094685","Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",[90],"2027-08-01","2030-11-01","2025-11-18",[1606,1607,1608,1609,1610],"Advanced Head and Neck Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma","Stage II Head and Neck Cutaneous Squamous Cell Carcinoma","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma",[1590],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"intervention":362,"totalTrials":138,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":138,"soonestReadout":354},[1626],{"nctId":351,"briefTitle":352,"status":212,"phases":1627,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":1628,"interventions":1629},[90],[359,360],[57,362],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"intervention":1637,"totalTrials":138,"cells":1638},"Chemoradiation",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":138,"soonestReadout":354},[1645],{"nctId":1646,"briefTitle":1647,"status":212,"phases":1648,"primaryCompletion":354,"completion":1649,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1655},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[90],"2030-12","2023-04-27",150,[1653,1654],"Oropharyngeal Cancer","Squamous Cell Carcinoma of the Oropharynx",[1637],{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[],{"intervention":117,"totalTrials":22,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":138,"soonestReadout":214},[1670,1674,1684,1688,1698,1702,1706,1714,1718,1727,1738],{"nctId":106,"briefTitle":107,"status":108,"phases":1671,"primaryCompletion":110,"completion":111,"start":112,"enrollment":36,"conditions":1672,"interventions":1673},[90],[114],[116,77,117,118],{"nctId":1675,"briefTitle":1676,"status":122,"phases":1677,"primaryCompletion":960,"completion":1205,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1681},"NCT00645593","Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer",[90],"2008-03",89,[27],[1682,117,1683],"Gemcitabine,","Cetuximab",{"nctId":154,"briefTitle":155,"status":122,"phases":1685,"primaryCompletion":157,"completion":158,"start":159,"conditions":1686,"interventions":1687},[90],[161],[77,117,118],{"nctId":1689,"briefTitle":1690,"status":122,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":865,"conditions":1695,"interventions":1696},"NCT00176813","Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer",[90],"2003-11","2006-11","2003-03",[21],[173,117,1697],"Celecoxib",{"nctId":670,"briefTitle":671,"status":122,"phases":1699,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":1700,"interventions":1701},[90],[677],[117,131],{"nctId":680,"briefTitle":681,"status":122,"phases":1703,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":1704,"interventions":1705},[90],[687],[689,690,117,131],{"nctId":1707,"briefTitle":1708,"status":108,"phases":1709,"primaryCompletion":158,"completion":110,"start":1710,"enrollment":363,"conditions":1711,"interventions":1713},"NCT00599131","Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)",[90],"2007-08",[1712],"Cancer of Larynx",[117,1683,118,690],{"nctId":825,"briefTitle":826,"status":122,"phases":1715,"primaryCompletion":828,"completion":829,"start":830,"enrollment":597,"conditions":1716,"interventions":1717},[90],[832],[173,117,761,152],{"nctId":1719,"briefTitle":1720,"status":108,"phases":1721,"primaryCompletion":1722,"completion":1723,"start":794,"enrollment":597,"conditions":1724,"interventions":1725},"NCT04203160","Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)",[89,90],"2024-04-16","2024-04-29",[772],[1726,173,117],"CPI 613",{"nctId":1728,"briefTitle":1729,"status":122,"phases":1730,"primaryCompletion":922,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1736},"NCT01661114","A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers",[90],"2016-03","2011-07",39,[21,1735],"Biliary Cancer",[173,1737,117],"5-FU",{"nctId":210,"briefTitle":211,"status":212,"phases":1739,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":1740,"interventions":1741},[90],[218,219,220,221,222],[131,117,77],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[1748],{"nctId":249,"briefTitle":250,"status":122,"phases":1749,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":1750,"interventions":1751},[93],[30],[77,131,117,118],{"intervention":1010,"totalTrials":865,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1778,"PHASE4":1795,"NA":1797},{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"trials":1759,"activeCount":138,"soonestReadout":46},[1760,1764,1774],{"nctId":44,"briefTitle":45,"status":319,"phases":1761,"primaryCompletion":46,"completion":1005,"start":1006,"enrollment":8,"conditions":1762,"interventions":1763},[90],[24],[47,1009,975,1010],{"nctId":1765,"briefTitle":1766,"status":122,"phases":1767,"primaryCompletion":1768,"completion":626,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1772},"NCT00116961","Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma",[90],"2007-01","2005-06",40,[24],[1773,1021,1010],"Velcade",{"nctId":1012,"briefTitle":1013,"status":122,"phases":1775,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1776,"interventions":1777},[89,90],[24],[1009,975,1010,1021],{"trials":1779,"activeCount":100},[1780],{"nctId":1781,"briefTitle":1782,"status":108,"phases":1783,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1790},"NCT04503668","Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients",[91],"2024-01-03","2024-03-11","2020-12-28",62,[1789],"Gynecologic Cancer",[1791,1010,1792,1793,1794],"Ondansetron","Neurokinin-1 Receptor Antagonist","Olanzapine","Compazine",{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[1799],{"nctId":1800,"briefTitle":1801,"status":122,"phases":1802,"primaryCompletion":136,"completion":626,"start":1803,"enrollment":461,"conditions":1804,"interventions":1805},"NCT00135187","Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma",[93],"2004-07",[24],[1806,1021,1010],"VELCADE",{"intervention":1808,"totalTrials":138,"cells":1809},"Yttrium-90",{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":138,"soonestReadout":1818},[1814],{"nctId":1815,"briefTitle":1816,"status":212,"phases":1817,"primaryCompletion":1818,"completion":1176,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1823},"NCT04518748","Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.",[89],"2028-05","2020-09-16",70,[1822],"Liver Malignancy",[1808],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[],{"intervention":1833,"totalTrials":138,"cells":1834},"Gilteritinib",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1836,"activeCount":100},[],{"trials":1838,"activeCount":138,"soonestReadout":583},[1839],{"nctId":1840,"briefTitle":1841,"status":212,"phases":1842,"primaryCompletion":583,"completion":583,"start":1843,"enrollment":461,"conditions":1844,"interventions":1847},"NCT06225427","Gilteritinib for the Treatment of ALK NSCLC",[89],"2024-07-25",[1845,1846],"Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8",[1833],{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"intervention":1857,"totalTrials":138,"cells":1858},"Ad-hCMV-Flt3L",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1876,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":138,"soonestReadout":1867},[1863],{"nctId":1864,"briefTitle":1865,"status":212,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":25,"conditions":1869,"interventions":1873},"NCT06914479","Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors",[89],"2031-05","2026-05-22",[1870,1871,1872],"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant","Recurrent Malignant Brain Neoplasm","Resectable Brain Neoplasm",[1857,1874,1875],"Ad-hCMV-TK","Valacyclovir",{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":100},[],{"intervention":1874,"totalTrials":138,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1894,"PHASE3":1896,"PHASE4":1898,"NA":1900},{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":138,"soonestReadout":1867},[1890],{"nctId":1864,"briefTitle":1865,"status":212,"phases":1891,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":25,"conditions":1892,"interventions":1893},[89],[1870,1871,1872],[1857,1874,1875],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[],{"intervention":1875,"totalTrials":138,"cells":1903},{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1918},{"trials":1905,"activeCount":100},[],{"trials":1907,"activeCount":138,"soonestReadout":1867},[1908],{"nctId":1864,"briefTitle":1865,"status":212,"phases":1909,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":25,"conditions":1910,"interventions":1911},[89],[1870,1871,1872],[1857,1874,1875],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[],{"intervention":81,"totalTrials":138,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1931,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1923,"activeCount":100},[],{"trials":1925,"activeCount":138,"soonestReadout":76},[1926],{"nctId":79,"briefTitle":80,"status":212,"phases":1927,"primaryCompletion":76,"completion":1045,"start":1928,"enrollment":461,"conditions":1929,"interventions":1930},[89],"2024-02-27",[15],[81],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"intervention":1940,"totalTrials":138,"cells":1941},"Pomalidomide",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":138,"soonestReadout":1951},[1946],{"nctId":1947,"briefTitle":1948,"status":1949,"phases":1950,"primaryCompletion":1951,"completion":1389,"start":1952,"enrollment":22,"conditions":1953,"interventions":1958},"NCT07532525","Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma","NOT_YET_RECRUITING",[89],"2027-07","2026-05-01",[1954,1955,1956,1957],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B-Cell Non-Hodgkin Lymphoma",[1940],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[],{"intervention":1968,"totalTrials":138,"cells":1969},"Gallium Ga 68-DOTA-FAPI-04",{"EARLY_PHASE1":1970,"PHASE1":1981,"PHASE2":1983,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1971,"activeCount":138,"soonestReadout":1976},[1972],{"nctId":1973,"briefTitle":1974,"status":212,"phases":1975,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":461,"conditions":1978,"interventions":1980},"NCT07132645","An Investigational Scan ([68Ga] Ga-FAPI-04 PET\u002FCT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer",[88],"2027-09-01","2025-09-16",[1979],"Neuroendocrine Tumor",[1968],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":100},[],{"intervention":1992,"totalTrials":9,"cells":1993},"Abemaciclib 150 MG",{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2010,"PHASE4":2012,"NA":2026},{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[2000],{"nctId":2001,"briefTitle":2002,"status":177,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":100,"conditions":2006,"interventions":2007},"NCT04272645","Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer",[90],"2022-10","2020-10",[18],[2008,2009,1992],"Abemaciclib 200 MG","Atezolizumab 1200 MG in 20 ML",{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[2014],{"nctId":2015,"briefTitle":2016,"status":177,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":100,"conditions":2020,"interventions":2022},"NCT05691400","Phase IV Multi-arm Study of CDK4\u002F6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype",[92],"2027-03","2024-03",[2021],"CYP3A4*22",[2023,2024,2025],"Palbociclib 125Mg Tab","Ribociclib 200Mg Oral","Abemaciclib 150 MG Oral",{"trials":2027,"activeCount":100},[],{"intervention":2023,"totalTrials":138,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2038,"NA":2044},{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[2040],{"nctId":2015,"briefTitle":2016,"status":177,"phases":2041,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":100,"conditions":2042,"interventions":2043},[92],[2021],[2023,2024,2025],{"trials":2045,"activeCount":100},[],{"intervention":2024,"totalTrials":138,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2062},{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":100},[],{"trials":2053,"activeCount":100},[],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[2058],{"nctId":2015,"briefTitle":2016,"status":177,"phases":2059,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":100,"conditions":2060,"interventions":2061},[92],[2021],[2023,2024,2025],{"trials":2063,"activeCount":100},[],{"intervention":2065,"totalTrials":138,"cells":2066},"Vismodegib",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2087},{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[2077],{"nctId":2078,"briefTitle":2079,"status":122,"phases":2080,"primaryCompletion":2081,"completion":2081,"start":2082,"enrollment":2083,"conditions":2084,"interventions":2086},"NCT02436408","VISmodegib for ORbital and Periocular Basal Cell Carcinoma",[92],"2020-09","2015-07-15",35,[2085],"Carcinoma, Basal Cell",[2065],{"trials":2088,"activeCount":100},[],{"intervention":2090,"totalTrials":865,"cells":2091},"Etanercept",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2128,"PHASE4":2139,"NA":2141},{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[],{"trials":2097,"activeCount":100},[2098,2106,2110,2121],{"nctId":2099,"briefTitle":2100,"status":122,"phases":2101,"primaryCompletion":2102,"completion":2103,"start":202,"enrollment":1178,"conditions":2104,"interventions":2105},"NCT00141739","Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)",[90],"2011-08","2012-09",[903],[2090],{"nctId":878,"briefTitle":879,"status":122,"phases":2107,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":2108,"interventions":2109},[90],[886],[888,889,890,891],{"nctId":2111,"briefTitle":2112,"status":122,"phases":2113,"primaryCompletion":158,"completion":2114,"start":2115,"enrollment":770,"conditions":2116,"interventions":2120},"NCT00141726","Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant",[90],"2009-02","2003-10",[2117,2118,2119],"Lung Injury, Acute","Respiratory Distress Syndrome, Adult","Bronchiolitis Obliterans",[2090],{"nctId":2122,"briefTitle":2123,"status":122,"phases":2124,"primaryCompletion":1693,"completion":2125,"start":2115,"enrollment":1770,"conditions":2126,"interventions":2127},"NCT00141713","The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease",[90],"2006-12",[903],[2090],{"trials":2129,"activeCount":100},[2130],{"nctId":2131,"briefTitle":2132,"status":122,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":1017,"enrollment":770,"conditions":2136,"interventions":2138},"NCT00726375","The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease",[91],"2013-07","2014-09",[2137],"Acute Graft Versus Host Disease",[2090],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"intervention":1791,"totalTrials":138,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2157,"NA":2159},{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[2153],{"nctId":1781,"briefTitle":1782,"status":108,"phases":2154,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":2155,"interventions":2156},[91],[1789],[1791,1010,1792,1793,1794],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"intervention":1792,"totalTrials":138,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2169,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":100},[],{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[2171],{"nctId":1781,"briefTitle":1782,"status":108,"phases":2172,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":2173,"interventions":2174},[91],[1789],[1791,1010,1792,1793,1794],{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"intervention":1793,"totalTrials":138,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[],{"trials":2188,"activeCount":100},[2189],{"nctId":1781,"briefTitle":1782,"status":108,"phases":2190,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":2191,"interventions":2192},[91],[1789],[1791,1010,1792,1793,1794],{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"intervention":1794,"totalTrials":138,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":100},[],{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"trials":2206,"activeCount":100},[2207],{"nctId":1781,"briefTitle":1782,"status":108,"phases":2208,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":2209,"interventions":2210},[91],[1789],[1791,1010,1792,1793,1794],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"intervention":173,"totalTrials":2216,"cells":2217},14,{"EARLY_PHASE1":2218,"PHASE1":2230,"PHASE2":2242,"PHASE3":2312,"PHASE4":2314,"NA":2316},{"trials":2219,"activeCount":100},[2220],{"nctId":2221,"briefTitle":2222,"status":177,"phases":2223,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":100,"conditions":2226,"interventions":2229},"NCT04051047","Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma",[88],"2021-12","2019-11-30",[2227,2228,452],"Glial Tumor of Brain","Diffuse Intrinsic Pontine Glioma",[173],{"trials":2231,"activeCount":100},[2232],{"nctId":2233,"briefTitle":2234,"status":122,"phases":2235,"primaryCompletion":911,"completion":2236,"start":2237,"enrollment":22,"conditions":2238,"interventions":2239},"NCT01663272","A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer",[89],"2017-03-01","2012-07",[21],[2240,2241],"CABOZANTINIB","gemcitabine",{"trials":2243,"activeCount":100},[2244,2248,2259,2263,2267,2271,2281,2285,2294,2298,2302,2308],{"nctId":622,"briefTitle":623,"status":122,"phases":2245,"primaryCompletion":625,"completion":625,"start":626,"enrollment":487,"conditions":2246,"interventions":2247},[90],[27],[629,131,173],{"nctId":2249,"briefTitle":2250,"status":122,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":1770,"conditions":2255,"interventions":2257},"NCT00242190","Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer",[89,90],"2006-03","2010-02","2004-06",[2256],"Pancreatic Neoplasms",[2258,2241],"oxaliplatin",{"nctId":164,"briefTitle":165,"status":122,"phases":2260,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":2261,"interventions":2262},[90],[27],[77,131,173],{"nctId":660,"briefTitle":661,"status":108,"phases":2264,"primaryCompletion":663,"completion":168,"start":664,"conditions":2265,"interventions":2266},[90],[666],[131,173,668],{"nctId":1689,"briefTitle":1690,"status":122,"phases":2268,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":865,"conditions":2269,"interventions":2270},[90],[21],[173,117,1697],{"nctId":2272,"briefTitle":2273,"status":122,"phases":2274,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":770,"conditions":2277,"interventions":2279},"NCT02037230","Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas",[89,90],"2018-08","2014-01",[2278],"Adenocarcinoma of the Pancreas",[2280,173],"MK-1775",{"nctId":825,"briefTitle":826,"status":122,"phases":2282,"primaryCompletion":828,"completion":829,"start":830,"enrollment":597,"conditions":2283,"interventions":2284},[90],[832],[173,117,761,152],{"nctId":2286,"briefTitle":2287,"status":122,"phases":2288,"primaryCompletion":2289,"completion":2290,"start":1090,"enrollment":2291,"conditions":2292,"interventions":2293},"NCT00456599","Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer",[90],"2012-05","2013-01",71,[21],[2241,2258],{"nctId":199,"briefTitle":200,"status":122,"phases":2295,"primaryCompletion":202,"completion":168,"start":203,"enrollment":204,"conditions":2296,"interventions":2297},[90],[206],[208,77,131,173],{"nctId":1719,"briefTitle":1720,"status":108,"phases":2299,"primaryCompletion":1722,"completion":1723,"start":794,"enrollment":597,"conditions":2300,"interventions":2301},[89,90],[772],[1726,173,117],{"nctId":2303,"briefTitle":2304,"status":122,"phases":2305,"primaryCompletion":2289,"completion":898,"start":192,"enrollment":216,"conditions":2306,"interventions":2307},"NCT00593866","Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer",[89,90],[21],[173],{"nctId":1728,"briefTitle":1729,"status":122,"phases":2309,"primaryCompletion":922,"completion":1731,"start":1732,"enrollment":1733,"conditions":2310,"interventions":2311},[90],[21,1735],[173,1737,117],{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"trials":2317,"activeCount":100},[],{"intervention":208,"totalTrials":363,"cells":2319},{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2335,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[2324],{"nctId":2325,"briefTitle":2326,"status":122,"phases":2327,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":25,"conditions":2331,"interventions":2332},"NCT03135171","Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab",[89],"2020-03-16","2020-03-20","2017-07-26",[15],[208,2333,2334],"Pertuzumab","Tocilizumab",{"trials":2336,"activeCount":100},[2337,2344,2348],{"nctId":2338,"briefTitle":2339,"status":108,"phases":2340,"primaryCompletion":252,"completion":110,"start":158,"enrollment":138,"conditions":2341,"interventions":2342},"NCT00726180","Use of Trastuzumab to Induce Increased ER Expression in ER-negative\u002FLow, Her-2\u002FNeu Positive Breast Cancer",[89,90],[15],[2343],"trastuzumab",{"nctId":199,"briefTitle":200,"status":122,"phases":2345,"primaryCompletion":202,"completion":168,"start":203,"enrollment":204,"conditions":2346,"interventions":2347},[90],[206],[208,77,131,173],{"nctId":2349,"briefTitle":2350,"status":122,"phases":2351,"primaryCompletion":2352,"completion":2353,"start":2354,"enrollment":231,"conditions":2355,"interventions":2357},"NCT00146042","UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer",[90],"2004-03","2005-03","1999-03",[2356],"HER-2 Positive Metastatic Breast Cancer",[690,208],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[],{"intervention":2365,"totalTrials":371,"cells":2366},"Tetrathiomolybdate",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2402,"PHASE4":2404,"NA":2406},{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[2373,2385,2396],{"nctId":2374,"briefTitle":2375,"status":122,"phases":2376,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":2380,"conditions":2381,"interventions":2383},"NCT00176774","Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma",[90],"2004-02","2004-04","2001-02",24,[2382],"Colorectal Carcinoma",[2384,118,775,2365],"Irinotecan",{"nctId":2386,"briefTitle":2387,"status":122,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":2393,"interventions":2395},"NCT00176800","Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma",[90],"2006-02","2013-05","2001-11",69,[2394],"Esophageal Carcinoma",[2365],{"nctId":2397,"briefTitle":2398,"status":122,"phases":2399,"primaryCompletion":2115,"completion":663,"start":664,"enrollment":1391,"conditions":2400,"interventions":2401},"NCT00150995","Tetrathiomolybdate in Hormone Refractory Prostate Cancer",[90],[18],[2365],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"intervention":2409,"totalTrials":371,"cells":2410},"Cabozantinib",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2419,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[2415],{"nctId":2233,"briefTitle":2234,"status":122,"phases":2416,"primaryCompletion":911,"completion":2236,"start":2237,"enrollment":22,"conditions":2417,"interventions":2418},[89],[21],[2240,2241],{"trials":2420,"activeCount":100},[2421,2430],{"nctId":2422,"briefTitle":2423,"status":108,"phases":2424,"primaryCompletion":2425,"completion":2425,"start":2426,"enrollment":371,"conditions":2427,"interventions":2429},"NCT04497038","Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy",[89,90],"2023-05-02","2021-08-06",[2428],"Advanced Adult Hepatocellular Carcinoma",[2409],{"nctId":2431,"briefTitle":2432,"status":108,"phases":2433,"primaryCompletion":898,"completion":2434,"start":2435,"enrollment":294,"conditions":2436,"interventions":2437},"NCT01428219","Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone",[90],"2015-09","2012-02",[325],[2409],{"trials":2439,"activeCount":100},[],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"intervention":186,"totalTrials":371,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[2452,2456,2460],{"nctId":289,"briefTitle":290,"status":108,"phases":2453,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":2454,"interventions":2455},[89,90],[296],[57,186,131,298],{"nctId":175,"briefTitle":176,"status":177,"phases":2457,"primaryCompletion":179,"start":180,"enrollment":100,"conditions":2458,"interventions":2459},[90],[182],[184,131,185,77,186],{"nctId":342,"briefTitle":343,"status":122,"phases":2461,"primaryCompletion":345,"completion":345,"start":346,"enrollment":204,"conditions":2462,"interventions":2463},[90],[348],[57,131,186],{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"intervention":746,"totalTrials":371,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2480,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[2476],{"nctId":737,"briefTitle":738,"status":108,"phases":2477,"primaryCompletion":740,"completion":740,"start":741,"enrollment":36,"conditions":2478,"interventions":2479},[89],[743],[745,152,746],{"trials":2481,"activeCount":100},[2482,2490],{"nctId":2483,"briefTitle":2484,"status":122,"phases":2485,"primaryCompletion":2125,"completion":1768,"start":2486,"enrollment":2083,"conditions":2487,"interventions":2489},"NCT00143871","Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma",[90],"2001-04",[2488],"Lymphoma, Non-Hodgkin's",[746],{"nctId":2491,"briefTitle":2492,"status":108,"phases":2493,"primaryCompletion":2353,"completion":167,"start":1694,"enrollment":461,"conditions":2494,"interventions":2495},"NCT00141700","Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma",[90],[2488],[746],{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"intervention":196,"totalTrials":371,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[2510,2518,2529],{"nctId":2511,"briefTitle":2512,"status":122,"phases":2513,"primaryCompletion":2352,"completion":136,"start":2514,"enrollment":204,"conditions":2515,"interventions":2516},"NCT00151086","Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer",[89,90],"2001-12",[18],[196,2517],"Vinorelbine",{"nctId":2519,"briefTitle":2520,"status":122,"phases":2521,"primaryCompletion":2522,"completion":2523,"start":2524,"enrollment":19,"conditions":2525,"interventions":2527},"NCT00151073","Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate",[90],"2005-09","2007-09","2002-04",[2526],"Hormone-Refractory Prostate Cancer",[2528,196,690],"Zoledronic acid",{"nctId":188,"briefTitle":189,"status":122,"phases":2530,"primaryCompletion":191,"completion":192,"start":193,"enrollment":19,"conditions":2531,"interventions":2532},[90],[18],[196,197,77],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"intervention":629,"totalTrials":9,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2560,"PHASE4":2562,"NA":2564},{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[],{"trials":2546,"activeCount":100},[2547,2551],{"nctId":622,"briefTitle":623,"status":122,"phases":2548,"primaryCompletion":625,"completion":625,"start":626,"enrollment":487,"conditions":2549,"interventions":2550},[90],[27],[629,131,173],{"nctId":2552,"briefTitle":2553,"status":108,"phases":2554,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":270,"conditions":2557,"interventions":2559},"NCT00995488","Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer",[90],"2013-11","2009-10",[2558,27],"Urothelial Cancer",[629],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"intervention":2258,"totalTrials":9,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":100},[],{"trials":2573,"activeCount":100},[2574,2578],{"nctId":2249,"briefTitle":2250,"status":122,"phases":2575,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":1770,"conditions":2576,"interventions":2577},[89,90],[2256],[2258,2241],{"nctId":2286,"briefTitle":2287,"status":122,"phases":2579,"primaryCompletion":2289,"completion":2290,"start":1090,"enrollment":2291,"conditions":2580,"interventions":2581},[90],[21],[2241,2258],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[],{"trials":2587,"activeCount":100},[],{"intervention":2384,"totalTrials":9,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[2596,2600],{"nctId":2374,"briefTitle":2375,"status":122,"phases":2597,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":2380,"conditions":2598,"interventions":2599},[90],[2382],[2384,118,775,2365],{"nctId":2601,"briefTitle":2602,"status":122,"phases":2603,"primaryCompletion":2604,"completion":1678,"start":2605,"enrollment":986,"conditions":2606,"interventions":2607},"NCT00230399","Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer",[90],"2006-01","2003-06",[33],[1697,668,2384],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"intervention":775,"totalTrials":9,"cells":2615},{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[2622,2626],{"nctId":2374,"briefTitle":2375,"status":122,"phases":2623,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":2380,"conditions":2624,"interventions":2625},[90],[2382],[2384,118,775,2365],{"nctId":765,"briefTitle":766,"status":122,"phases":2627,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":2628,"interventions":2629},[89,90],[772],[152,774,118,775],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[],{"intervention":298,"totalTrials":9,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2639,"activeCount":100},[],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[2644,2648],{"nctId":777,"briefTitle":778,"status":122,"phases":2645,"primaryCompletion":780,"completion":781,"start":782,"enrollment":16,"conditions":2646,"interventions":2647},[90],[772],[298,152],{"nctId":289,"briefTitle":290,"status":108,"phases":2649,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":2650,"interventions":2651},[89,90],[296],[57,186,131,298],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"intervention":1002,"totalTrials":9,"cells":2659},{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2661,"activeCount":100},[],{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[2666,2670],{"nctId":995,"briefTitle":996,"status":177,"phases":2667,"primaryCompletion":998,"completion":999,"start":959,"enrollment":100,"conditions":2668,"interventions":2669},[90],[403],[975,1002],{"nctId":1163,"briefTitle":1164,"status":177,"phases":2671,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":100,"conditions":2672,"interventions":2673},[89,90],[1155,1169],[1139,1002],{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"intervention":2681,"totalTrials":9,"cells":2682},"Metformin",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2684,"activeCount":100},[],{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[2689,2698],{"nctId":2690,"briefTitle":2691,"status":122,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":912,"conditions":2695,"interventions":2697},"NCT01750567","A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL",[90],"2025-02-28","2012-11",[2696],"Relapsed Chronic Lymphocytic Leukemia",[2681],{"nctId":2699,"briefTitle":2700,"status":122,"phases":2701,"primaryCompletion":1204,"completion":2702,"start":2703,"enrollment":254,"conditions":2704,"interventions":2706},"NCT01579812","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",[90],"2017-07","2011-10",[2705],"Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[2681],{"trials":2708,"activeCount":100},[],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"intervention":799,"totalTrials":9,"cells":2714},{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[2721,2725],{"nctId":790,"briefTitle":791,"status":122,"phases":2722,"primaryCompletion":793,"completion":794,"start":795,"enrollment":96,"conditions":2723,"interventions":2724},[89,90],[797],[799,152],{"nctId":2726,"briefTitle":2727,"status":108,"phases":2728,"completion":2729,"start":2730,"enrollment":2731,"conditions":2732,"interventions":2734},"NCT00176761","Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine",[90],"2006-05","2000-03",27,[2733],"Metastatic Colorectal Cancer",[799],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"intervention":1697,"totalTrials":9,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[2749,2753],{"nctId":1689,"briefTitle":1690,"status":122,"phases":2750,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":865,"conditions":2751,"interventions":2752},[90],[21],[173,117,1697],{"nctId":2601,"briefTitle":2602,"status":122,"phases":2754,"primaryCompletion":2604,"completion":1678,"start":2605,"enrollment":986,"conditions":2755,"interventions":2756},[90],[33],[1697,668,2384],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"intervention":2764,"totalTrials":9,"cells":2765},"Dasatinib",{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":100},[2772,2784],{"nctId":2773,"briefTitle":2774,"status":177,"phases":2775,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":100,"conditions":2779,"interventions":2780},"NCT04845035","Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[90],"2026-01","2029-01","2024-01",[274],[2764,2781,2782,2783],"Ponatinib","Berlin-Frankfurt-Münster Chemotherapy","Methotrexate and Cytarabine",{"nctId":2785,"briefTitle":2786,"status":108,"phases":2787,"primaryCompletion":2788,"completion":1151,"start":2789,"enrollment":371,"conditions":2790,"interventions":2793},"NCT03352427","Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations",[90],"2019-04-17","2017-12-06",[452,2791,2792],"High Grade Glioma","Pontine Tumors",[2764,2794],"Everolimus",{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"intervention":689,"totalTrials":9,"cells":2802},{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[2809,2813],{"nctId":680,"briefTitle":681,"status":122,"phases":2810,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":2811,"interventions":2812},[90],[687],[689,690,117,131],{"nctId":2814,"briefTitle":2815,"status":108,"phases":2816,"primaryCompletion":2817,"completion":2434,"start":252,"enrollment":2083,"conditions":2818,"interventions":2820},"NCT01285635","A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck",[90],"2012-12",[2819],"Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[689,690],{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"trials":2826,"activeCount":100},[],{"intervention":2334,"totalTrials":9,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2837,"PHASE3":2846,"PHASE4":2848,"NA":2850},{"trials":2830,"activeCount":100},[],{"trials":2832,"activeCount":100},[2833],{"nctId":2325,"briefTitle":2326,"status":122,"phases":2834,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":25,"conditions":2835,"interventions":2836},[89],[15],[208,2333,2334],{"trials":2838,"activeCount":100},[2839],{"nctId":2840,"briefTitle":2841,"status":177,"phases":2842,"primaryCompletion":959,"completion":2843,"start":2702,"enrollment":100,"conditions":2844,"interventions":2845},"NCT02997956","Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)",[89,90],"2022-07",[562],[2334],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[],{"intervention":2853,"totalTrials":9,"cells":2854},"Imatinib",{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":100},[],{"trials":2860,"activeCount":100},[2861,2869],{"nctId":2862,"briefTitle":2863,"status":108,"phases":2864,"primaryCompletion":1017,"completion":2865,"start":2377,"enrollment":25,"conditions":2866,"interventions":2868},"NCT00115739","Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma",[90],"2010-08",[2867],"Thyroid Cancer",[2853],{"nctId":2870,"briefTitle":2871,"status":177,"phases":2872,"primaryCompletion":179,"completion":2873,"start":2874,"enrollment":100,"conditions":2875,"interventions":2877},"NCT01188889","RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w\u002F Molecular Disease.",[89,90],"2017-12","2013-09",[2876],"Chronic Myeloid Leukemia",[2878,2853],"RAD001",{"trials":2880,"activeCount":100},[],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[],{"intervention":2794,"totalTrials":9,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[2893,2897],{"nctId":2785,"briefTitle":2786,"status":108,"phases":2894,"primaryCompletion":2788,"completion":1151,"start":2789,"enrollment":371,"conditions":2895,"interventions":2896},[90],[452,2791,2792],[2764,2794],{"nctId":2898,"briefTitle":2899,"status":177,"phases":2900,"primaryCompletion":2901,"completion":2901,"start":2902,"enrollment":100,"conditions":2903,"interventions":2904},"NCT03632317","A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas",[90],"2025-10","2019-10",[452,2228],[2905,2794],"Panobinostat",{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"intervention":2913,"totalTrials":9,"cells":2914},"Axitinib",{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[2921,2929],{"nctId":2922,"briefTitle":2923,"status":122,"phases":2924,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":487,"conditions":2927,"interventions":2928},"NCT02762513","Expansion Trial for Axitinib In Head And Neck Cancer",[90],"2020-04-09","2016-08-30",[677],[2913],{"nctId":2930,"briefTitle":2931,"status":122,"phases":2932,"primaryCompletion":2933,"completion":1731,"start":881,"enrollment":2934,"conditions":2935,"interventions":2937},"NCT01469546","Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer",[90],"2015-04",42,[2936],"Head and Neck Squamous Cell Carcinoma",[2913],{"trials":2939,"activeCount":100},[],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"intervention":184,"totalTrials":9,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2958,"PHASE2":2960,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2947,"activeCount":100},[2948],{"nctId":2949,"briefTitle":2950,"status":122,"phases":2951,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":496,"conditions":2954,"interventions":2956},"NCT06378398","A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy",[88],"2026-02-17","2024-06-14",[2955],"Colorectal Neoplasia",[184,2957],"Aspirin",{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[2962],{"nctId":175,"briefTitle":176,"status":177,"phases":2963,"primaryCompletion":179,"start":180,"enrollment":100,"conditions":2964,"interventions":2965},[90],[182],[184,131,185,77,186],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[],{"intervention":2973,"totalTrials":9,"cells":2974},"Clofarabine\u002FBusulfan x 4",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":3003,"PHASE4":3005,"NA":3007},{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[2981,2991],{"nctId":2982,"briefTitle":2983,"status":122,"phases":2984,"primaryCompletion":2985,"completion":2986,"start":2987,"enrollment":597,"conditions":2988,"interventions":2990},"NCT01457885","Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen",[90],"2014-11","2016-06-14","2011-11",[2989],"Acute Myeloblastic Leukemia",[2973],{"nctId":2992,"briefTitle":2993,"status":122,"phases":2994,"primaryCompletion":2995,"completion":2103,"start":168,"enrollment":2996,"conditions":2997,"interventions":3002},"NCT00556452","Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen",[89,90],"2011-06",46,[2998,2999,3000,24,3001],"Leukemia","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Myelodysplastic Syndrome",[2973],{"trials":3004,"activeCount":100},[],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"intervention":3010,"totalTrials":138,"cells":3011},"MK-0752, Docetaxel, Pegfilgrastim",{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[3018],{"nctId":3019,"briefTitle":3020,"status":122,"phases":3021,"primaryCompletion":3022,"completion":3023,"start":1678,"enrollment":461,"conditions":3024,"interventions":3025},"NCT00645333","Phase I\u002FII Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer",[89,90],"2010-01","2012-10",[35],[3010],{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"intervention":3033,"totalTrials":138,"cells":3034},"Lapatinib and Paclitaxel",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[3041],{"nctId":3042,"briefTitle":3043,"status":177,"phases":3044,"primaryCompletion":3045,"completion":3046,"start":2694,"enrollment":100,"conditions":3047,"interventions":3048},"NCT01700010","Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer",[90],"2017-01","2019-01",[2558,27],[3033],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"intervention":116,"totalTrials":138,"cells":3056},{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[3063],{"nctId":106,"briefTitle":107,"status":108,"phases":3064,"primaryCompletion":110,"completion":111,"start":112,"enrollment":36,"conditions":3065,"interventions":3066},[90],[114],[116,77,117,118],{"trials":3068,"activeCount":100},[],{"trials":3070,"activeCount":100},[],{"trials":3072,"activeCount":100},[],{"intervention":3074,"totalTrials":138,"cells":3075},"SUTENT",{"EARLY_PHASE1":3076,"PHASE1":3078,"PHASE2":3080,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[3082],{"nctId":3083,"briefTitle":3084,"status":108,"phases":3085,"primaryCompletion":3086,"completion":2817,"start":2729,"enrollment":3087,"conditions":3088,"interventions":3089},"NCT00393796","Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma",[90],"2011-12",54,[27],[3074],{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[],{"intervention":774,"totalTrials":138,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3108,"PHASE4":3110,"NA":3112},{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[3104],{"nctId":765,"briefTitle":766,"status":122,"phases":3105,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":3106,"interventions":3107},[89,90],[772],[152,774,118,775],{"trials":3109,"activeCount":100},[],{"trials":3111,"activeCount":100},[],{"trials":3113,"activeCount":100},[],{"intervention":3115,"totalTrials":138,"cells":3116},"Fezolinetant",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[3123],{"nctId":3124,"briefTitle":3125,"status":108,"phases":3126,"primaryCompletion":3127,"completion":3128,"start":3129,"enrollment":28,"conditions":3130,"interventions":3132},"NCT06617455","Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial",[90],"2025-10-22","2025-11-21","2024-10-31",[599,600,601,3131,1368],"Breast Ductal Carcinoma In Situ",[3115],{"trials":3134,"activeCount":100},[],{"trials":3136,"activeCount":100},[],{"trials":3138,"activeCount":100},[],{"intervention":1682,"totalTrials":138,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3151,"PHASE4":3153,"NA":3155},{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[3147],{"nctId":1675,"briefTitle":1676,"status":122,"phases":3148,"primaryCompletion":960,"completion":1205,"start":1678,"enrollment":1679,"conditions":3149,"interventions":3150},[90],[27],[1682,117,1683],{"trials":3152,"activeCount":100},[],{"trials":3154,"activeCount":100},[],{"trials":3156,"activeCount":100},[],{"intervention":3158,"totalTrials":138,"cells":3159},"Calcitriol",{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3164,"PHASE3":3174,"PHASE4":3176,"NA":3178},{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[3166],{"nctId":3167,"briefTitle":3168,"status":108,"phases":3169,"primaryCompletion":2703,"completion":3170,"start":419,"enrollment":770,"conditions":3171,"interventions":3173},"NCT00794547","Phase I\u002FII Calcitriol in Lung Cancer",[89,90],"2013-08",[3172],"Non Small Cell Lung Cancer",[3158,3158],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[],{"intervention":2517,"totalTrials":138,"cells":3181},{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3183,"activeCount":100},[],{"trials":3185,"activeCount":100},[],{"trials":3187,"activeCount":100},[3188],{"nctId":2511,"briefTitle":2512,"status":122,"phases":3189,"primaryCompletion":2352,"completion":136,"start":2514,"enrollment":204,"conditions":3190,"interventions":3191},[89,90],[18],[196,2517],{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[],{"intervention":1208,"totalTrials":138,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3201,"activeCount":100},[],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[3206],{"nctId":1201,"briefTitle":1202,"status":122,"phases":3207,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":16,"conditions":3208,"interventions":3209},[90],[24],[1208,1009,1209],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[],{"trials":3215,"activeCount":100},[],{"intervention":1209,"totalTrials":138,"cells":3217},{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3219,"activeCount":100},[],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[3224],{"nctId":1201,"briefTitle":1202,"status":122,"phases":3225,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":16,"conditions":3226,"interventions":3227},[90],[24],[1208,1009,1209],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"intervention":3235,"totalTrials":138,"cells":3236},"Ibrance",{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[3243],{"nctId":3244,"briefTitle":3245,"status":122,"phases":3246,"primaryCompletion":3247,"completion":3248,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3252},"NCT02059213","A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer",[90],"2017-09-09","2019-06-04","2014-06",72,[18],[3235,3253,3254,3255],"Bicalutamide","Zoladex","Lupron Depot",{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"intervention":3253,"totalTrials":138,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3265,"activeCount":100},[],{"trials":3267,"activeCount":100},[],{"trials":3269,"activeCount":100},[3270],{"nctId":3244,"briefTitle":3245,"status":122,"phases":3271,"primaryCompletion":3247,"completion":3248,"start":3249,"enrollment":3250,"conditions":3272,"interventions":3273},[90],[18],[3235,3253,3254,3255],{"trials":3275,"activeCount":100},[],{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[],{"intervention":3254,"totalTrials":138,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3283,"activeCount":100},[],{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":100},[3288],{"nctId":3244,"briefTitle":3245,"status":122,"phases":3289,"primaryCompletion":3247,"completion":3248,"start":3249,"enrollment":3250,"conditions":3290,"interventions":3291},[90],[18],[3235,3253,3254,3255],{"trials":3293,"activeCount":100},[],{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"intervention":3255,"totalTrials":138,"cells":3299},{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3310,"PHASE4":3312,"NA":3314},{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[3306],{"nctId":3244,"briefTitle":3245,"status":122,"phases":3307,"primaryCompletion":3247,"completion":3248,"start":3249,"enrollment":3250,"conditions":3308,"interventions":3309},[90],[18],[3235,3253,3254,3255],{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":100},[],{"trials":3315,"activeCount":100},[],{"intervention":424,"totalTrials":138,"cells":3317},{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[3324],{"nctId":414,"briefTitle":415,"status":122,"phases":3325,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":3326,"interventions":3327},[90],[422],[424,425,52],{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[],{"intervention":425,"totalTrials":138,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3346,"PHASE4":3348,"NA":3350},{"trials":3337,"activeCount":100},[],{"trials":3339,"activeCount":100},[],{"trials":3341,"activeCount":100},[3342],{"nctId":414,"briefTitle":415,"status":122,"phases":3343,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":3344,"interventions":3345},[90],[422],[424,425,52],{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"intervention":3353,"totalTrials":138,"cells":3354},"WNT974",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3369,"PHASE4":3371,"NA":3373},{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[3361],{"nctId":3362,"briefTitle":3363,"status":177,"phases":3364,"primaryCompletion":3365,"enrollment":100,"conditions":3366,"interventions":3368},"NCT02649530","A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",[90],"2018-07",[3367],"Squamous Cell Carcinoma, Head And Neck",[3353],{"trials":3370,"activeCount":100},[],{"trials":3372,"activeCount":100},[],{"trials":3374,"activeCount":100},[],{"intervention":3376,"totalTrials":138,"cells":3377},"Venetoclax",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3395,"PHASE4":3397,"NA":3399},{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[3384],{"nctId":3385,"briefTitle":3386,"status":108,"phases":3387,"primaryCompletion":3388,"completion":3388,"start":3389,"enrollment":3390,"conditions":3391,"interventions":3393},"NCT05780879","A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia",[90],"2025-08-16","2024-06-03",10,[3392],"Secondary Acute Myeloid Leukemia",[3376,3394],"FLAG or CLAG Protocol",{"trials":3396,"activeCount":100},[],{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[],{"intervention":3394,"totalTrials":138,"cells":3402},{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3413,"PHASE4":3415,"NA":3417},{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[3409],{"nctId":3385,"briefTitle":3386,"status":108,"phases":3410,"primaryCompletion":3388,"completion":3388,"start":3389,"enrollment":3390,"conditions":3411,"interventions":3412},[90],[3392],[3376,3394],{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"intervention":889,"totalTrials":138,"cells":3420},{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3422,"activeCount":100},[],{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[3427],{"nctId":878,"briefTitle":879,"status":122,"phases":3428,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":3429,"interventions":3430},[90],[886],[888,889,890,891],{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"intervention":891,"totalTrials":138,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[3445],{"nctId":878,"briefTitle":879,"status":122,"phases":3446,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":3447,"interventions":3448},[90],[886],[888,889,890,891],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"trials":3454,"activeCount":100},[],{"intervention":2280,"totalTrials":138,"cells":3456},{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3467,"PHASE4":3469,"NA":3471},{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[3463],{"nctId":2272,"briefTitle":2273,"status":122,"phases":3464,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":770,"conditions":3465,"interventions":3466},[89,90],[2278],[2280,173],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"trials":3472,"activeCount":100},[],{"intervention":3474,"totalTrials":138,"cells":3475},"PTK787",{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[3482],{"nctId":3483,"briefTitle":3484,"status":122,"phases":3485,"primaryCompletion":1693,"completion":3486,"start":3487,"enrollment":865,"conditions":3488,"interventions":3489},"NCT00134355","Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer",[90],"2007-03","2005-07",[18],[3474],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[],{"trials":3495,"activeCount":100},[],{"intervention":3497,"totalTrials":138,"cells":3498},"Fludarabine",{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[3505],{"nctId":3506,"briefTitle":3507,"status":122,"phases":3508,"primaryCompletion":111,"completion":3509,"start":3486,"enrollment":852,"conditions":3510,"interventions":3512},"NCT00623935","Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia",[90],"2015-11",[3511],"Acute Myelogenous Leukemia",[3497,3513],"Busulfan",{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"intervention":3513,"totalTrials":138,"cells":3521},{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[3528],{"nctId":3506,"briefTitle":3507,"status":122,"phases":3529,"primaryCompletion":111,"completion":3509,"start":3486,"enrollment":852,"conditions":3530,"interventions":3531},[90],[3511],[3497,3513],{"trials":3533,"activeCount":100},[],{"trials":3535,"activeCount":100},[],{"trials":3537,"activeCount":100},[],{"intervention":2781,"totalTrials":138,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3544,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[3546],{"nctId":2773,"briefTitle":2774,"status":177,"phases":3547,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":100,"conditions":3548,"interventions":3549},[90],[274],[2764,2781,2782,2783],{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[],{"intervention":2782,"totalTrials":138,"cells":3557},{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[3564],{"nctId":2773,"briefTitle":2774,"status":177,"phases":3565,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":100,"conditions":3566,"interventions":3567},[90],[274],[2764,2781,2782,2783],{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[],{"intervention":2783,"totalTrials":138,"cells":3575},{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3577,"activeCount":100},[],{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[3582],{"nctId":2773,"briefTitle":2774,"status":177,"phases":3583,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":100,"conditions":3584,"interventions":3585},[90],[274],[2764,2781,2782,2783],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[],{"intervention":3593,"totalTrials":138,"cells":3594},"Tumor lysate-pulsed dendritic cell (DC) vaccine",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[3601],{"nctId":3602,"briefTitle":3603,"status":122,"phases":3604,"primaryCompletion":3605,"completion":252,"start":192,"enrollment":270,"conditions":3606,"interventions":3609},"NCT00405327","A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation",[90],"2009-06",[489,3607,3608],"Neuroblastoma","Wilm's Tumor",[3593],{"trials":3611,"activeCount":100},[],{"trials":3613,"activeCount":100},[],{"trials":3615,"activeCount":100},[],{"intervention":2008,"totalTrials":138,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":100},[],{"trials":3621,"activeCount":100},[],{"trials":3623,"activeCount":100},[3624],{"nctId":2001,"briefTitle":2002,"status":177,"phases":3625,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":100,"conditions":3626,"interventions":3627},[90],[18],[2008,2009,1992],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[],{"intervention":2009,"totalTrials":138,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3640,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3637,"activeCount":100},[],{"trials":3639,"activeCount":100},[],{"trials":3641,"activeCount":100},[3642],{"nctId":2001,"briefTitle":2002,"status":177,"phases":3643,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":100,"conditions":3644,"interventions":3645},[90],[18],[2008,2009,1992],{"trials":3647,"activeCount":100},[],{"trials":3649,"activeCount":100},[],{"trials":3651,"activeCount":100},[],{"intervention":3653,"totalTrials":138,"cells":3654},"ifosfamide and doxorubicin vs gemcitabine and docetaxel",{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3669,"PHASE4":3671,"NA":3673},{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[3661],{"nctId":3662,"briefTitle":3663,"status":122,"phases":3664,"primaryCompletion":2694,"completion":418,"start":202,"enrollment":3665,"conditions":3666,"interventions":3668},"NCT00189137","Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma",[90],84,[3667],"Sarcoma, Soft Tissue",[3653],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"intervention":699,"totalTrials":138,"cells":3676},{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3678,"activeCount":100},[],{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[3683],{"nctId":692,"briefTitle":693,"status":122,"phases":3684,"primaryCompletion":695,"completion":486,"start":696,"enrollment":496,"conditions":3685,"interventions":3686},[90],[677],[699,131],{"trials":3688,"activeCount":100},[],{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"intervention":3694,"totalTrials":138,"cells":3695},"SOC Carboplatin",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3713,"PHASE4":3715,"NA":3717},{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[3702],{"nctId":3703,"briefTitle":3704,"status":122,"phases":3705,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":1770,"conditions":3709,"interventions":3711},"NCT02784288","Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer",[90],"2020-07-10","2022-07-12","2016-10-31",[3710],"Oropharyngeal Squamous Cell Cancer",[3694,3712],"SOC Paclitaxel",{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"intervention":3712,"totalTrials":138,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3722,"activeCount":100},[],{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[3727],{"nctId":3703,"briefTitle":3704,"status":122,"phases":3728,"primaryCompletion":3706,"completion":3707,"start":3708,"enrollment":1770,"conditions":3729,"interventions":3730},[90],[3710],[3694,3712],{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"intervention":3738,"totalTrials":138,"cells":3739},"carfilzomib, lenalidomide plus dexamethasone",{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3744,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3741,"activeCount":100},[],{"trials":3743,"activeCount":100},[],{"trials":3745,"activeCount":100},[3746],{"nctId":3747,"briefTitle":3748,"status":122,"phases":3749,"primaryCompletion":3086,"completion":3750,"start":1089,"enrollment":899,"conditions":3751,"interventions":3752},"NCT01029054","Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma",[89,90],"2015-07",[24],[3738,3738],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"intervention":185,"totalTrials":138,"cells":3760},{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[],{"trials":3766,"activeCount":100},[3767],{"nctId":175,"briefTitle":176,"status":177,"phases":3768,"primaryCompletion":179,"start":180,"enrollment":100,"conditions":3769,"interventions":3770},[90],[182],[184,131,185,77,186],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"intervention":492,"totalTrials":138,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[3785],{"nctId":481,"briefTitle":482,"status":122,"phases":3786,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":3787,"interventions":3788},[90],[489,490],[42,492],{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"intervention":3796,"totalTrials":138,"cells":3797},"AG 6013736",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[3804],{"nctId":3805,"briefTitle":3806,"status":122,"phases":3807,"primaryCompletion":136,"completion":3605,"start":3487,"enrollment":371,"conditions":3808,"interventions":3809},"NCT00176748","Treatment for Patients With Metastatic Thyroid Cancer",[90],[2867],[3796],{"trials":3811,"activeCount":100},[],{"trials":3813,"activeCount":100},[],{"trials":3815,"activeCount":100},[],{"intervention":3817,"totalTrials":138,"cells":3818},"Bob's Red Mill®",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3820,"activeCount":100},[],{"trials":3822,"activeCount":100},[],{"trials":3824,"activeCount":100},[3825],{"nctId":3826,"briefTitle":3827,"status":122,"phases":3828,"primaryCompletion":3829,"completion":3829,"start":3830,"enrollment":3831,"conditions":3832,"interventions":3834},"NCT02763033","Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients",[90],"2025-12-29","2017-04-26",107,[3833],"Hematopoietic Stem Cell Transplantation",[3817],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"intervention":2528,"totalTrials":138,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[3849],{"nctId":2519,"briefTitle":2520,"status":122,"phases":3850,"primaryCompletion":2522,"completion":2523,"start":2524,"enrollment":19,"conditions":3851,"interventions":3852},[90],[2526],[2528,196,690],{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"intervention":905,"totalTrials":138,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[3867],{"nctId":893,"briefTitle":894,"status":122,"phases":3868,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":3869,"interventions":3870},[89,90],[901,902,903],[905,410],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"intervention":3878,"totalTrials":138,"cells":3879},"Bexxar",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"trials":3885,"activeCount":100},[3886],{"nctId":3887,"briefTitle":3888,"status":108,"phases":3889,"primaryCompletion":674,"completion":3890,"start":1732,"enrollment":231,"conditions":3891,"interventions":3892},"NCT01389076","Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma",[90],"2016-06",[404],[3878,3893],"Low Dose Methotrexate",{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[],{"trials":3899,"activeCount":100},[],{"intervention":3893,"totalTrials":138,"cells":3901},{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3906,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":100},[],{"trials":3907,"activeCount":100},[3908],{"nctId":3887,"briefTitle":3888,"status":108,"phases":3909,"primaryCompletion":674,"completion":3890,"start":1732,"enrollment":231,"conditions":3910,"interventions":3911},[90],[404],[3878,3893],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"intervention":197,"totalTrials":138,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[3926],{"nctId":188,"briefTitle":189,"status":122,"phases":3927,"primaryCompletion":191,"completion":192,"start":193,"enrollment":19,"conditions":3928,"interventions":3929},[90],[18],[196,197,77],{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[],{"trials":3935,"activeCount":100},[],{"intervention":3937,"totalTrials":138,"cells":3938},"Gleevec",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[3945],{"nctId":3946,"briefTitle":3947,"status":122,"phases":3948,"primaryCompletion":2604,"completion":663,"start":3949,"enrollment":420,"conditions":3950,"interventions":3952},"NCT00156286","Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC",[90],"2002-03",[3951],"Small Cell Lung Cancer",[3937],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"trials":3958,"activeCount":100},[],{"intervention":844,"totalTrials":138,"cells":3960},{"EARLY_PHASE1":3961,"PHASE1":3963,"PHASE2":3965,"PHASE3":3971,"PHASE4":3973,"NA":3975},{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[3967],{"nctId":835,"briefTitle":836,"status":122,"phases":3968,"primaryCompletion":838,"completion":839,"start":840,"enrollment":363,"conditions":3969,"interventions":3970},[90],[842],[152,844],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"intervention":3978,"totalTrials":138,"cells":3979},"Cyclophosphamide and Sirolimus",{"EARLY_PHASE1":3980,"PHASE1":3982,"PHASE2":3984,"PHASE3":3995,"PHASE4":3997,"NA":3999},{"trials":3981,"activeCount":100},[],{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[3986],{"nctId":3987,"briefTitle":3988,"status":122,"phases":3989,"primaryCompletion":3990,"completion":2103,"start":3991,"enrollment":11,"conditions":3992,"interventions":3994},"NCT00743509","A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma",[90],"2010-04","2008-08",[3993],"Osteosarcoma",[3978],{"trials":3996,"activeCount":100},[],{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"intervention":317,"totalTrials":138,"cells":4002},{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4007,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[4009],{"nctId":309,"briefTitle":310,"status":122,"phases":4010,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":4011,"interventions":4012},[90],[285],[57,317],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"intervention":1726,"totalTrials":138,"cells":4020},{"EARLY_PHASE1":4021,"PHASE1":4023,"PHASE2":4025,"PHASE3":4031,"PHASE4":4033,"NA":4035},{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[4027],{"nctId":1719,"briefTitle":1720,"status":108,"phases":4028,"primaryCompletion":1722,"completion":1723,"start":794,"enrollment":597,"conditions":4029,"interventions":4030},[89,90],[772],[1726,173,117],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"intervention":4038,"totalTrials":138,"cells":4039},"Iodine I 131 Tositumomab",{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":4047,"briefTitle":4048,"status":122,"phases":4049,"primaryCompletion":3170,"completion":4050,"start":4051,"enrollment":270,"conditions":4052,"interventions":4053},"NCT00135200","Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma",[90],"2024-09-04","2005-08",[24],[4038],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"intervention":4061,"totalTrials":138,"cells":4062},"Romidepsin",{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":100},[],{"trials":4068,"activeCount":100},[4069],{"nctId":4070,"briefTitle":4071,"status":108,"phases":4072,"primaryCompletion":4073,"completion":4073,"start":4074,"enrollment":25,"conditions":4075,"interventions":4076},"NCT03547700","Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)",[89,90],"2020-08-27","2018-09-26",[1154],[4061,4077],"Ixazomib",{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"intervention":4077,"totalTrials":138,"cells":4085},{"EARLY_PHASE1":4086,"PHASE1":4088,"PHASE2":4090,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[4092],{"nctId":4070,"briefTitle":4071,"status":108,"phases":4093,"primaryCompletion":4073,"completion":4073,"start":4074,"enrollment":25,"conditions":4094,"interventions":4095},[89,90],[1154],[4061,4077],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"intervention":4103,"totalTrials":138,"cells":4104},"Alpha-1-Antitrypsin",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[4111],{"nctId":4112,"briefTitle":4113,"status":122,"phases":4114,"primaryCompletion":1167,"completion":4115,"start":2134,"enrollment":1770,"conditions":4116,"interventions":4117},"NCT01700036","A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease",[90],"2018-10-26",[924],[4103],{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"intervention":4125,"totalTrials":138,"cells":4126},"PEG-IFN-a2b",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[4133],{"nctId":4134,"briefTitle":4135,"status":108,"phases":4136,"primaryCompletion":110,"completion":4137,"start":2523,"enrollment":22,"conditions":4138,"interventions":4139},"NCT00573378","Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia",[90],"2015-12",[2876],[4125],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[],{"trials":4145,"activeCount":100},[],{"intervention":915,"totalTrials":138,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[4154],{"nctId":907,"briefTitle":908,"status":122,"phases":4155,"primaryCompletion":910,"completion":910,"start":911,"enrollment":912,"conditions":4156,"interventions":4157},[89,90],[273],[915,410,411],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"intervention":4165,"totalTrials":138,"cells":4166},"Pevonedistat",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[4173],{"nctId":4174,"briefTitle":4175,"status":108,"phases":4176,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":1770,"conditions":4179,"interventions":4180},"NCT03228186","Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer",[90],"2021-11-04","2018-03-05",[348],[4165,690],{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"intervention":4188,"totalTrials":138,"cells":4189},"amifostine trihydrate",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4191,"activeCount":100},[],{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[4196],{"nctId":4197,"briefTitle":4198,"status":122,"phases":4199,"primaryCompletion":2514,"completion":3949,"start":4200,"conditions":4201,"interventions":4202},"NCT00005598","Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome",[90],"2000-10",[272],[4188,4203],"azacitidine",{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":100},[],{"intervention":4203,"totalTrials":138,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[4218],{"nctId":4197,"briefTitle":4198,"status":122,"phases":4219,"primaryCompletion":2514,"completion":3949,"start":4200,"conditions":4220,"interventions":4221},[90],[272],[4188,4203],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"intervention":4229,"totalTrials":138,"cells":4230},"Devimistat",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4232,"activeCount":100},[],{"trials":4234,"activeCount":100},[],{"trials":4236,"activeCount":100},[4237],{"nctId":4238,"briefTitle":4239,"status":177,"phases":4240,"primaryCompletion":632,"completion":632,"start":4241,"enrollment":100,"conditions":4242,"interventions":4244},"NCT05926206","Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas",[89,90],"2023-07",[4243],"Metastatic Pancreatic Adenocarcinoma",[4229,4245],"Modified FOLFIRINOX",{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"intervention":4245,"totalTrials":138,"cells":4253},{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[4260],{"nctId":4238,"briefTitle":4239,"status":177,"phases":4261,"primaryCompletion":632,"completion":632,"start":4241,"enrollment":100,"conditions":4262,"interventions":4263},[89,90],[4243],[4229,4245],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"intervention":4271,"totalTrials":138,"cells":4272},"Cannabidiol",{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4288,"PHASE4":4290,"NA":4292},{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[4279],{"nctId":4280,"briefTitle":4281,"status":122,"phases":4282,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":1770,"conditions":4285,"interventions":4287},"NCT04754399","Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",[90],"2023-10-10","2021-04-16",[4286,15],"Arthralgia",[4271],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[],{"trials":4293,"activeCount":100},[],{"intervention":4295,"totalTrials":138,"cells":4296},"FOLFIRINOX",{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[4303],{"nctId":4304,"briefTitle":4305,"status":122,"phases":4306,"primaryCompletion":4307,"completion":4308,"start":2995,"enrollment":294,"conditions":4309,"interventions":4310},"NCT01661088","A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients",[90],"2017-08-10","2019-08-30",[21],[4295],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"intervention":4318,"totalTrials":138,"cells":4319},"Neoadjuvant Cisplatin and Gemcitabine",{"EARLY_PHASE1":4320,"PHASE1":4322,"PHASE2":4324,"PHASE3":4332,"PHASE4":4334,"NA":4336},{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[4326],{"nctId":4327,"briefTitle":4328,"status":108,"phases":4329,"primaryCompletion":2276,"completion":2276,"start":2103,"enrollment":138,"conditions":4330,"interventions":4331},"NCT01663285","Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)",[90],[2558,27],[4318],{"trials":4333,"activeCount":100},[],{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[],{"intervention":4339,"totalTrials":138,"cells":4340},"eflornithine",{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4357,"PHASE4":4359,"NA":4361},{"trials":4342,"activeCount":100},[],{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":100},[4347],{"nctId":4348,"briefTitle":4349,"status":122,"phases":4350,"primaryCompletion":4351,"completion":4352,"start":4353,"enrollment":4354,"conditions":4355,"interventions":4356},"NCT00003076","Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus",[90],"2002-06","2005-10","1995-10",152,[161],[4339],{"trials":4358,"activeCount":100},[],{"trials":4360,"activeCount":100},[],{"trials":4362,"activeCount":100},[],{"intervention":2878,"totalTrials":138,"cells":4364},{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4375,"PHASE4":4377,"NA":4379},{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[4371],{"nctId":2870,"briefTitle":2871,"status":177,"phases":4372,"primaryCompletion":179,"completion":2873,"start":2874,"enrollment":100,"conditions":4373,"interventions":4374},[89,90],[2876],[2878,2853],{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"intervention":4382,"totalTrials":138,"cells":4383},"MLN9708",{"EARLY_PHASE1":4384,"PHASE1":4386,"PHASE2":4388,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4385,"activeCount":100},[],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[4390],{"nctId":4391,"briefTitle":4392,"status":122,"phases":4393,"primaryCompletion":1167,"completion":4394,"start":2135,"enrollment":96,"conditions":4395,"interventions":4397},"NCT02158975","Open-label, Phase II Study of MLN9708 in Patients With Relapsed\u002FRefractory Cutaneous and Peripheral T-cell Lymphomas",[90],"2016-11",[4396],"Lymphoma, T-Cell",[4382],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"trials":4403,"activeCount":100},[],{"intervention":4405,"totalTrials":138,"cells":4406},"Mitomycin C",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4411,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4408,"activeCount":100},[],{"trials":4410,"activeCount":100},[],{"trials":4412,"activeCount":100},[4413],{"nctId":4414,"briefTitle":4415,"status":108,"phases":4416,"primaryCompletion":158,"completion":4417,"start":167,"enrollment":96,"conditions":4418,"interventions":4419},"NCT00271011","A Study of Mitomycin C, Irinotecan, and Cetuximab",[90],"2009-07",[33],[4405,1683,4420],"Irinotecan.",{"trials":4422,"activeCount":100},[],{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[],{"intervention":4420,"totalTrials":138,"cells":4428},{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[4435],{"nctId":4414,"briefTitle":4415,"status":108,"phases":4436,"primaryCompletion":158,"completion":4417,"start":167,"enrollment":96,"conditions":4437,"interventions":4438},[90],[33],[4405,1683,4420],{"trials":4440,"activeCount":100},[],{"trials":4442,"activeCount":100},[],{"trials":4444,"activeCount":100},[],{"intervention":4446,"totalTrials":138,"cells":4447},"68Ga-PSMA",{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[4454],{"nctId":4455,"briefTitle":4456,"status":108,"phases":4457,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":25,"conditions":4460,"interventions":4461},"NCT03689582","Radiolabeled Gallium-68 (68Ga-PSMA) for PET\u002FCT Imaging to Detect Prostate Cancer",[90],"2020-02-27","2018-11-13",[18],[4446],{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"intervention":4469,"totalTrials":138,"cells":4470},"Hormone therapy or chemotherapy",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":100},[4477],{"nctId":4478,"briefTitle":4479,"status":122,"phases":4480,"primaryCompletion":4481,"completion":4481,"start":4482,"enrollment":2216,"conditions":4483,"interventions":4484},"NCT03556904","FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)",[90],"2023-07-28","2018-12-10",[18],[4469],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[],{"intervention":2905,"totalTrials":138,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4503,"PHASE4":4505,"NA":4507},{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[4499],{"nctId":2898,"briefTitle":2899,"status":177,"phases":4500,"primaryCompletion":2901,"completion":2901,"start":2902,"enrollment":100,"conditions":4501,"interventions":4502},[90],[452,2228],[2905,2794],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"intervention":4510,"totalTrials":138,"cells":4511},"Fludarabine\u002FBusulfan x 4 days",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[4518],{"nctId":4519,"briefTitle":4520,"status":108,"phases":4521,"primaryCompletion":2817,"completion":2290,"start":4522,"enrollment":231,"conditions":4523,"interventions":4525},"NCT00615589","Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen",[90],"2008-02",[24,4524],"Plasma Cell Leukemia",[4510],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"intervention":4533,"totalTrials":138,"cells":4534},"Lamivudine",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4550,"PHASE4":4552,"NA":4554},{"trials":4536,"activeCount":100},[],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[4541],{"nctId":4542,"briefTitle":4543,"status":177,"phases":4544,"primaryCompletion":4545,"start":4137,"enrollment":100,"conditions":4546,"interventions":4548},"NCT01528865","Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma",[89,90],"2017-08",[4547],"Lymphoma",[4533,4549],"Tenofovir disoproxil fumarate",{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"trials":4555,"activeCount":100},[],{"intervention":4549,"totalTrials":138,"cells":4557},{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4568,"PHASE4":4570,"NA":4572},{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[4564],{"nctId":4542,"briefTitle":4543,"status":177,"phases":4565,"primaryCompletion":4545,"start":4137,"enrollment":100,"conditions":4566,"interventions":4567},[89,90],[4547],[4533,4549],{"trials":4569,"activeCount":100},[],{"trials":4571,"activeCount":100},[],{"trials":4573,"activeCount":100},[],{"intervention":1071,"totalTrials":138,"cells":4575},{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4577,"activeCount":100},[],{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[4582],{"nctId":1063,"briefTitle":1064,"status":177,"phases":4583,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":100,"conditions":4584,"interventions":4585},[89,90],[1069],[1071,991],{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[],{"intervention":4593,"totalTrials":138,"cells":4594},"ginger extract",{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[4601],{"nctId":4602,"briefTitle":4603,"status":122,"phases":4604,"primaryCompletion":4605,"start":4606,"enrollment":4607,"conditions":4608,"interventions":4611},"NCT00064272","UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer",[90],"2007-05","2003-05",180,[4609,4610],"Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific",[4593],{"trials":4613,"activeCount":100},[],{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"intervention":1737,"totalTrials":138,"cells":4619},{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4630,"PHASE4":4632,"NA":4634},{"trials":4621,"activeCount":100},[],{"trials":4623,"activeCount":100},[],{"trials":4625,"activeCount":100},[4626],{"nctId":1728,"briefTitle":1729,"status":122,"phases":4627,"primaryCompletion":922,"completion":1731,"start":1732,"enrollment":1733,"conditions":4628,"interventions":4629},[90],[21,1735],[173,1737,117],{"trials":4631,"activeCount":100},[],{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"intervention":4637,"totalTrials":138,"cells":4638},"Lapatinib",{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4640,"activeCount":100},[],{"trials":4642,"activeCount":100},[],{"trials":4644,"activeCount":100},[4645],{"nctId":4646,"briefTitle":4647,"status":108,"phases":4648,"primaryCompletion":192,"completion":2523,"start":4352,"enrollment":487,"conditions":4649,"interventions":4651},"NCT00239200","Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus",[90],[4650],"Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus",[4637],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"intervention":4659,"totalTrials":138,"cells":4660},"sunitinib",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4676,"PHASE4":4678,"NA":4680},{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":100},[],{"trials":4666,"activeCount":100},[4667],{"nctId":4668,"briefTitle":4669,"status":122,"phases":4670,"primaryCompletion":4671,"completion":4672,"start":2523,"enrollment":270,"conditions":4673,"interventions":4675},"NCT00616109","Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC",[90],"2009-12","2011-01",[4674],"Extensive-Stage Small Cell Lung Cancer",[4659],{"trials":4677,"activeCount":100},[],{"trials":4679,"activeCount":100},[],{"trials":4681,"activeCount":100},[],{"intervention":4683,"totalTrials":138,"cells":4684},"Palonosetron",{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4701,"PHASE4":4703,"NA":4705},{"trials":4686,"activeCount":100},[],{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[4691],{"nctId":4692,"briefTitle":4693,"status":108,"phases":4694,"primaryCompletion":2390,"completion":2390,"start":4695,"enrollment":371,"conditions":4696,"interventions":4700},"NCT00982995","Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients",[90],"2010-11",[4697,4698,4699],"Nausea","Vomiting","Terminally Ill",[4683],{"trials":4702,"activeCount":100},[],{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[],{"intervention":4708,"totalTrials":138,"cells":4709},"Alemtuzumab",{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4723,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[4714],{"nctId":4715,"briefTitle":4716,"status":108,"phases":4717,"primaryCompletion":110,"completion":110,"start":1678,"enrollment":371,"conditions":4718,"interventions":4722},"NCT00637390","A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian\u002FPrimary Peritoneal Cancer.",[89],[4719,4720,4721],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer",[4708],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[],{"intervention":4732,"totalTrials":138,"cells":4733},"Dendritic cell vaccination",{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4746,"PHASE3":4748,"PHASE4":4750,"NA":4752},{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[4738],{"nctId":4739,"briefTitle":4740,"status":108,"phases":4741,"primaryCompletion":419,"completion":3990,"start":4742,"enrollment":363,"conditions":4743,"interventions":4745},"NCT00843830","A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma",[89],"2006-10",[4744],"Metastatic Pancreatic Carcinoma",[4732],{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[],{"trials":4751,"activeCount":100},[],{"trials":4753,"activeCount":100},[],{"intervention":4755,"totalTrials":138,"cells":4756},"Talazoparib",{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4774,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[4761],{"nctId":4762,"briefTitle":4763,"status":122,"phases":4764,"primaryCompletion":4765,"completion":4766,"start":4767,"enrollment":148,"conditions":4768,"interventions":4772},"NCT04703920","Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",[89],"2024-12-01","2025-01-02","2021-03-04",[35,4769,4770,4771],"Metastatic Castration-resistant Prostate Cancer","Metastatic Ovarian Carcinoma","Metastic or Unresectable Pancreatic Adenocarcinoma",[4755,4773],"Belinostat",{"trials":4775,"activeCount":100},[],{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"intervention":4773,"totalTrials":138,"cells":4783},{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4792,"PHASE3":4794,"PHASE4":4796,"NA":4798},{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[4788],{"nctId":4762,"briefTitle":4763,"status":122,"phases":4789,"primaryCompletion":4765,"completion":4766,"start":4767,"enrollment":148,"conditions":4790,"interventions":4791},[89],[35,4769,4770,4771],[4755,4773],{"trials":4793,"activeCount":100},[],{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"intervention":4801,"totalTrials":138,"cells":4802},"Irinotecan and Bortezomib",{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4815,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[4807],{"nctId":4808,"briefTitle":4809,"status":122,"phases":4810,"primaryCompletion":2237,"completion":2237,"start":4811,"enrollment":4812,"conditions":4813,"interventions":4814},"NCT00644696","Study of Irinotecan and Bortezomib in Children With Recurrent\u002FRefractory Neuroblastoma",[89],"2008-04",18,[3607],[4801],{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":100},[],{"intervention":745,"totalTrials":138,"cells":4824},{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4833,"PHASE3":4835,"PHASE4":4837,"NA":4839},{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[4829],{"nctId":737,"briefTitle":738,"status":108,"phases":4830,"primaryCompletion":740,"completion":740,"start":741,"enrollment":36,"conditions":4831,"interventions":4832},[89],[743],[745,152,746],{"trials":4834,"activeCount":100},[],{"trials":4836,"activeCount":100},[],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"intervention":4842,"totalTrials":138,"cells":4843},"Veliparib",{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4855,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[4848],{"nctId":4849,"briefTitle":4850,"status":122,"phases":4851,"primaryCompletion":898,"completion":4852,"start":881,"enrollment":204,"conditions":4853,"interventions":4854},"NCT01477489","Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer",[89],"2017-10",[15],[4842],{"trials":4856,"activeCount":100},[],{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":100},[],{"intervention":4864,"totalTrials":138,"cells":4865},"Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L",{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4880,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[4870],{"nctId":4871,"briefTitle":4872,"status":122,"phases":4873,"primaryCompletion":4874,"completion":4875,"start":960,"enrollment":1391,"conditions":4876,"interventions":4879},"NCT01811992","Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma",[89],"2019-02","2021-01",[4877,4878],"Malignant Glioma","Glioblastoma Multiforme",[4864],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"intervention":2333,"totalTrials":138,"cells":4889},{"EARLY_PHASE1":4890,"PHASE1":4892,"PHASE2":4898,"PHASE3":4900,"PHASE4":4902,"NA":4904},{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[4894],{"nctId":2325,"briefTitle":2326,"status":122,"phases":4895,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":25,"conditions":4896,"interventions":4897},[89],[15],[208,2333,2334],{"trials":4899,"activeCount":100},[],{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[],{"intervention":1234,"totalTrials":138,"cells":4907},{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4916,"PHASE3":4918,"PHASE4":4920,"NA":4922},{"trials":4909,"activeCount":100},[],{"trials":4911,"activeCount":100},[4912],{"nctId":1227,"briefTitle":1228,"status":108,"phases":4913,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":28,"conditions":4914,"interventions":4915},[89],[18],[1234,1051],{"trials":4917,"activeCount":100},[],{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[],{"intervention":4925,"totalTrials":138,"cells":4926},"Pazopanib",{"EARLY_PHASE1":4927,"PHASE1":4937,"PHASE2":4939,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4928,"activeCount":100},[4929],{"nctId":4930,"briefTitle":4931,"status":122,"phases":4932,"primaryCompletion":4933,"completion":4933,"start":3890,"enrollment":270,"conditions":4934,"interventions":4936},"NCT02729194","Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",[88],"2017-09",[4935],"Carcinoma, Renal Cell",[4925],{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[],{"intervention":4948,"totalTrials":138,"cells":4949},"MPDL3280A",{"EARLY_PHASE1":4950,"PHASE1":4959,"PHASE2":4961,"PHASE3":4963,"PHASE4":4965,"NA":4967},{"trials":4951,"activeCount":100},[4952],{"nctId":4953,"briefTitle":4954,"status":122,"phases":4955,"primaryCompletion":4956,"completion":4956,"start":418,"enrollment":22,"conditions":4957,"interventions":4958},"NCT02463994","A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC",[88],"2018-11-07",[348],[4948],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"intervention":4970,"totalTrials":138,"cells":4971},"Erlotinib",{"EARLY_PHASE1":4972,"PHASE1":4983,"PHASE2":4985,"PHASE3":4987,"PHASE4":4989,"NA":4991},{"trials":4973,"activeCount":100},[4974],{"nctId":4975,"briefTitle":4976,"status":177,"phases":4977,"primaryCompletion":4978,"start":2434,"enrollment":100,"conditions":4979,"interventions":4981},"NCT02277457","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",[88],"2021-06",[4980],"Non-Small Cell Lung Cancer",[4970,4982],"Crizotinib",{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"intervention":4982,"totalTrials":138,"cells":4994},{"EARLY_PHASE1":4995,"PHASE1":5001,"PHASE2":5003,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4996,"activeCount":100},[4997],{"nctId":4975,"briefTitle":4976,"status":177,"phases":4998,"primaryCompletion":4978,"start":2434,"enrollment":100,"conditions":4999,"interventions":5000},[88],[4980],[4970,4982],{"trials":5002,"activeCount":100},[],{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"intervention":5012,"totalTrials":138,"cells":5013},"3-[18F]Fluoro-para-hydroxyphenethylguanidine",{"EARLY_PHASE1":5014,"PHASE1":5025,"PHASE2":5027,"PHASE3":5029,"PHASE4":5031,"NA":5033},{"trials":5015,"activeCount":100},[5016],{"nctId":5017,"briefTitle":5018,"status":122,"phases":5019,"primaryCompletion":5020,"completion":5020,"start":5021,"enrollment":16,"conditions":5022,"interventions":5023},"NCT04510311","Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors",[88],"2024-12-31","2020-10-19",[326],[5012,5024],"[123I] metaiodobenzylguanidine",{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"trials":5030,"activeCount":100},[],{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[],{"intervention":5024,"totalTrials":138,"cells":5036},{"EARLY_PHASE1":5037,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5051},{"trials":5038,"activeCount":100},[5039],{"nctId":5017,"briefTitle":5018,"status":122,"phases":5040,"primaryCompletion":5020,"completion":5020,"start":5021,"enrollment":16,"conditions":5041,"interventions":5042},[88],[326],[5012,5024],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[],{"intervention":5054,"totalTrials":138,"cells":5055},"Potato starch",{"EARLY_PHASE1":5056,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5057,"activeCount":100},[5058],{"nctId":5059,"briefTitle":5060,"status":122,"phases":5061,"primaryCompletion":1230,"completion":1230,"start":5062,"enrollment":22,"conditions":5063,"interventions":5064},"NCT04552418","Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors",[88],"2021-06-02",[856],[5054],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[],{"intervention":5076,"totalTrials":138,"cells":5077},"Atezolizumab",{"EARLY_PHASE1":5078,"PHASE1":5089,"PHASE2":5091,"PHASE3":5093,"PHASE4":5095,"NA":5097},{"trials":5079,"activeCount":100},[5080],{"nctId":5081,"briefTitle":5082,"status":108,"phases":5083,"primaryCompletion":5084,"completion":5084,"start":5085,"enrollment":138,"conditions":5086,"interventions":5087},"NCT03208712","Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy",[88],"2018-08-02","2017-11-01",[285],[5076,5088],"Radium-223",{"trials":5090,"activeCount":100},[],{"trials":5092,"activeCount":100},[],{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[],{"intervention":5088,"totalTrials":138,"cells":5100},{"EARLY_PHASE1":5101,"PHASE1":5107,"PHASE2":5109,"PHASE3":5111,"PHASE4":5113,"NA":5115},{"trials":5102,"activeCount":100},[5103],{"nctId":5081,"briefTitle":5082,"status":108,"phases":5104,"primaryCompletion":5084,"completion":5084,"start":5085,"enrollment":138,"conditions":5105,"interventions":5106},[88],[285],[5076,5088],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[],{"trials":5114,"activeCount":100},[],{"trials":5116,"activeCount":100},[],{"intervention":2957,"totalTrials":138,"cells":5118},{"EARLY_PHASE1":5119,"PHASE1":5125,"PHASE2":5127,"PHASE3":5129,"PHASE4":5131,"NA":5133},{"trials":5120,"activeCount":100},[5121],{"nctId":2949,"briefTitle":2950,"status":122,"phases":5122,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":496,"conditions":5123,"interventions":5124},[88],[2955],[184,2957],{"trials":5126,"activeCount":100},[],{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[],{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[],{"intervention":690,"totalTrials":22,"cells":5136},{"EARLY_PHASE1":5137,"PHASE1":5139,"PHASE2":5145,"PHASE3":5200,"PHASE4":5202,"NA":5204},{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[5141],{"nctId":1085,"briefTitle":1086,"status":108,"phases":5142,"primaryCompletion":1088,"completion":1089,"start":1090,"enrollment":22,"conditions":5143,"interventions":5144},[89],[1092,18,27,285],[1094,1095],{"trials":5146,"activeCount":100},[5147,5154,5158,5162,5166,5173,5177,5181,5188,5196],{"nctId":5148,"briefTitle":5149,"status":108,"phases":5150,"primaryCompletion":3170,"completion":5151,"start":3486,"enrollment":1391,"conditions":5152,"interventions":5153},"NCT00480857","Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy",[90],"2014-07",[18],[690],{"nctId":680,"briefTitle":681,"status":122,"phases":5155,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":5156,"interventions":5157},[90],[687],[689,690,117,131],{"nctId":1707,"briefTitle":1708,"status":108,"phases":5159,"primaryCompletion":158,"completion":110,"start":1710,"enrollment":363,"conditions":5160,"interventions":5161},[90],[1712],[117,1683,118,690],{"nctId":2519,"briefTitle":2520,"status":122,"phases":5163,"primaryCompletion":2522,"completion":2523,"start":2524,"enrollment":19,"conditions":5164,"interventions":5165},[90],[2526],[2528,196,690],{"nctId":5167,"briefTitle":5168,"status":122,"phases":5169,"primaryCompletion":5170,"completion":168,"start":1694,"enrollment":986,"conditions":5171,"interventions":5172},"NCT00151047","Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer",[90],"2005-01",[18],[668,690],{"nctId":4174,"briefTitle":4175,"status":108,"phases":5174,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":1770,"conditions":5175,"interventions":5176},[90],[348],[4165,690],{"nctId":2814,"briefTitle":2815,"status":108,"phases":5178,"primaryCompletion":2817,"completion":2434,"start":252,"enrollment":2083,"conditions":5179,"interventions":5180},[90],[2819],[689,690],{"nctId":5182,"briefTitle":5183,"status":122,"phases":5184,"primaryCompletion":5185,"completion":2389,"start":2354,"enrollment":323,"conditions":5186,"interventions":5187},"NCT00148070","Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer",[90],"2004-09",[35],[690],{"nctId":5189,"briefTitle":5190,"status":122,"phases":5191,"primaryCompletion":3991,"completion":5192,"start":5193,"enrollment":1770,"conditions":5194,"interventions":5195},"NCT00148122","A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer",[90],"2010-07","2002-11",[30],[690,668],{"nctId":2349,"briefTitle":2350,"status":122,"phases":5197,"primaryCompletion":2352,"completion":2353,"start":2354,"enrollment":231,"conditions":5198,"interventions":5199},[90],[2356],[690,208],{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[5206],{"nctId":5207,"briefTitle":5208,"status":122,"phases":5209,"primaryCompletion":5210,"completion":5211,"start":5212,"enrollment":294,"conditions":5213,"interventions":5214},"NCT00156312","Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine",[93],"2005-05","2007-02","2003-07",[15],[690,668],{"intervention":668,"totalTrials":31,"cells":5216},{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5246,"PHASE4":5248,"NA":5250},{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"trials":5222,"activeCount":100},[5223,5227,5231,5235,5242],{"nctId":660,"briefTitle":661,"status":108,"phases":5224,"primaryCompletion":663,"completion":168,"start":664,"conditions":5225,"interventions":5226},[90],[666],[131,173,668],{"nctId":2601,"briefTitle":2602,"status":122,"phases":5228,"primaryCompletion":2604,"completion":1678,"start":2605,"enrollment":986,"conditions":5229,"interventions":5230},[90],[33],[1697,668,2384],{"nctId":5167,"briefTitle":5168,"status":122,"phases":5232,"primaryCompletion":5170,"completion":168,"start":1694,"enrollment":986,"conditions":5233,"interventions":5234},[90],[18],[668,690],{"nctId":5236,"briefTitle":5237,"status":108,"phases":5238,"primaryCompletion":5210,"completion":112,"start":4200,"enrollment":461,"conditions":5239,"interventions":5241},"NCT00176787","Radiation Therapy With Capecitabine in Rectal Cancer",[90],[5240],"Rectal Cancer",[668],{"nctId":5189,"briefTitle":5190,"status":122,"phases":5243,"primaryCompletion":3991,"completion":5192,"start":5193,"enrollment":1770,"conditions":5244,"interventions":5245},[90],[30],[690,668],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[5252,5256],{"nctId":5207,"briefTitle":5208,"status":122,"phases":5253,"primaryCompletion":5210,"completion":5211,"start":5212,"enrollment":294,"conditions":5254,"interventions":5255},[93],[15],[690,668],{"nctId":5257,"briefTitle":5258,"status":108,"phases":5259,"completion":4051,"start":2514,"conditions":5260,"interventions":5261},"NCT00176735","Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer",[93],[21],[668],{"intervention":118,"totalTrials":36,"cells":5263},{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5268,"PHASE3":5290,"PHASE4":5292,"NA":5294},{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[],{"trials":5269,"activeCount":100},[5270,5274,5278,5282,5286],{"nctId":106,"briefTitle":107,"status":108,"phases":5271,"primaryCompletion":110,"completion":111,"start":112,"enrollment":36,"conditions":5272,"interventions":5273},[90],[114],[116,77,117,118],{"nctId":2374,"briefTitle":2375,"status":122,"phases":5275,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":2380,"conditions":5276,"interventions":5277},[90],[2382],[2384,118,775,2365],{"nctId":765,"briefTitle":766,"status":122,"phases":5279,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":5280,"interventions":5281},[89,90],[772],[152,774,118,775],{"nctId":154,"briefTitle":155,"status":122,"phases":5283,"primaryCompletion":157,"completion":158,"start":159,"conditions":5284,"interventions":5285},[90],[161],[77,117,118],{"nctId":1707,"briefTitle":1708,"status":108,"phases":5287,"primaryCompletion":158,"completion":110,"start":1710,"enrollment":363,"conditions":5288,"interventions":5289},[90],[1712],[117,1683,118,690],{"trials":5291,"activeCount":100},[],{"trials":5293,"activeCount":100},[],{"trials":5295,"activeCount":100},[5296],{"nctId":249,"briefTitle":250,"status":122,"phases":5297,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":5298,"interventions":5299},[93],[30],[77,131,117,118],{"intervention":1683,"totalTrials":36,"cells":5301},{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5306,"PHASE3":5333,"PHASE4":5335,"NA":5337},{"trials":5303,"activeCount":100},[],{"trials":5305,"activeCount":100},[],{"trials":5307,"activeCount":100},[5308,5312,5318,5322,5326],{"nctId":1675,"briefTitle":1676,"status":122,"phases":5309,"primaryCompletion":960,"completion":1205,"start":1678,"enrollment":1679,"conditions":5310,"interventions":5311},[90],[27],[1682,117,1683],{"nctId":5313,"briefTitle":5314,"status":122,"phases":5315,"primaryCompletion":158,"completion":4671,"start":1769,"enrollment":314,"conditions":5316,"interventions":5317},"NCT00148109","Trial of Cetuximab in Patients With Metastatic and\u002For Locally Advanced Soft Tissue and Bony Sarcomas",[90],[489],[1683,1683],{"nctId":1707,"briefTitle":1708,"status":108,"phases":5319,"primaryCompletion":158,"completion":110,"start":1710,"enrollment":363,"conditions":5320,"interventions":5321},[90],[1712],[117,1683,118,690],{"nctId":4414,"briefTitle":4415,"status":108,"phases":5323,"primaryCompletion":158,"completion":4417,"start":167,"enrollment":96,"conditions":5324,"interventions":5325},[90],[33],[4405,1683,4420],{"nctId":5327,"briefTitle":5328,"status":108,"phases":5329,"primaryCompletion":5330,"completion":5330,"start":1015,"enrollment":357,"conditions":5331,"interventions":5332},"NCT00904345","Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)",[90],"2020-12",[30],[1683],{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[5339],{"nctId":5340,"briefTitle":5341,"status":122,"phases":5342,"primaryCompletion":5343,"completion":5343,"start":4672,"enrollment":396,"conditions":5344,"interventions":5346},"NCT01663259","Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients",[93],"2019-09",[1654,5345],"HPV",[1683],{"intervention":1021,"totalTrials":371,"cells":5348},{"EARLY_PHASE1":5349,"PHASE1":5351,"PHASE2":5353,"PHASE3":5363,"PHASE4":5365,"NA":5367},{"trials":5350,"activeCount":100},[],{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[5355,5359],{"nctId":1765,"briefTitle":1766,"status":122,"phases":5356,"primaryCompletion":1768,"completion":626,"start":1769,"enrollment":1770,"conditions":5357,"interventions":5358},[90],[24],[1773,1021,1010],{"nctId":1012,"briefTitle":1013,"status":122,"phases":5360,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":5361,"interventions":5362},[89,90],[24],[1009,975,1010,1021],{"trials":5364,"activeCount":100},[],{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[5369],{"nctId":1800,"briefTitle":1801,"status":122,"phases":5370,"primaryCompletion":136,"completion":626,"start":1803,"enrollment":461,"conditions":5371,"interventions":5372},[93],[24],[1806,1021,1010],{"intervention":247,"totalTrials":9,"cells":5374},{"EARLY_PHASE1":5375,"PHASE1":5385,"PHASE2":5387,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5376,"activeCount":100},[5377],{"nctId":5378,"briefTitle":5379,"status":177,"phases":5380,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":100,"conditions":5383,"interventions":5384},"NCT03235869","Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma",[88],"2023-03-01","2018-03-01",[359],[247],{"trials":5386,"activeCount":100},[],{"trials":5388,"activeCount":100},[],{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[5395],{"nctId":238,"briefTitle":239,"status":122,"phases":5396,"primaryCompletion":241,"completion":242,"start":243,"enrollment":11,"conditions":5397,"interventions":5398},[93],[245],[131,77,247],{"intervention":1806,"totalTrials":9,"cells":5400},{"EARLY_PHASE1":5401,"PHASE1":5403,"PHASE2":5405,"PHASE3":5411,"PHASE4":5413,"NA":5415},{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[5407],{"nctId":1765,"briefTitle":1766,"status":122,"phases":5408,"primaryCompletion":1768,"completion":626,"start":1769,"enrollment":1770,"conditions":5409,"interventions":5410},[90],[24],[1773,1021,1010],{"trials":5412,"activeCount":100},[],{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[5417],{"nctId":1800,"briefTitle":1801,"status":122,"phases":5418,"primaryCompletion":136,"completion":626,"start":1803,"enrollment":461,"conditions":5419,"interventions":5420},[93],[24],[1806,1021,1010],{"intervention":5422,"totalTrials":9,"cells":5423},"Duloxetine",{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5428,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[5430],{"nctId":5431,"briefTitle":5432,"status":122,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":5436,"conditions":5437,"interventions":5439},"NCT01912612","Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain",[90],"2019-06-28","2013-10-30",82,[5438],"Pain",[5422],{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[5446],{"nctId":5447,"briefTitle":5448,"status":122,"phases":5449,"primaryCompletion":4695,"completion":2703,"start":5450,"enrollment":2083,"conditions":5451,"interventions":5452},"NCT01028352","Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain",[93],"2008-10",[15],[5422],{"intervention":5454,"totalTrials":9,"cells":5455},"Anastrozole",{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5469,"PHASE4":5471,"NA":5473},{"trials":5457,"activeCount":100},[],{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[5462],{"nctId":5463,"briefTitle":5464,"status":108,"phases":5465,"primaryCompletion":3086,"completion":2874,"start":1710,"enrollment":2392,"conditions":5466,"interventions":5467},"NCT00555477","Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure",[90],[15],[5468],"anastrozole",{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[5475],{"nctId":5476,"briefTitle":5477,"status":122,"phases":5478,"primaryCompletion":2237,"completion":5479,"start":4417,"enrollment":216,"conditions":5480,"interventions":5481},"NCT01814397","Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients",[],"2013-02",[15,5438,4286],[5454,5482,5483],"exemestane","letrozole",{"intervention":5485,"totalTrials":138,"cells":5486},"GIFT",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5493,"PHASE4":5495,"NA":5497},{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[5499],{"nctId":5500,"briefTitle":5501,"status":122,"phases":5502,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":5506,"conditions":5507,"interventions":5509},"NCT05552664","The Genetic Information and Family Testing (GIFT) Study",[93],"2025-07-10","2025-08-10","2022-10-24",3002,[5508],"Cancer",[5485],{"intervention":5511,"totalTrials":138,"cells":5512},"DPYD or UGT1A1 variants",{"EARLY_PHASE1":5513,"PHASE1":5515,"PHASE2":5517,"PHASE3":5519,"PHASE4":5521,"NA":5523},{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"trials":5518,"activeCount":100},[],{"trials":5520,"activeCount":100},[],{"trials":5522,"activeCount":100},[],{"trials":5524,"activeCount":100},[5525],{"nctId":5526,"briefTitle":5527,"status":122,"phases":5528,"primaryCompletion":5529,"completion":5529,"start":5530,"enrollment":270,"conditions":5531,"interventions":5532},"NCT05583422","Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy",[],"2024-06-17","2023-08-18",[5508],[5511],{"intervention":5534,"totalTrials":138,"cells":5535},"tretinoin",{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5542,"PHASE4":5544,"NA":5546},{"trials":5537,"activeCount":100},[],{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[5548],{"nctId":5549,"briefTitle":5550,"status":122,"phases":5551,"primaryCompletion":5552,"completion":5553,"start":5554,"enrollment":4607,"conditions":5555,"interventions":5558},"NCT00003598","UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia",[93],"2001-03","2009-11","1999-01",[5556,5557],"Cervical Cancer","Precancerous\u002FNonmalignant Condition",[5534],{"intervention":5560,"totalTrials":138,"cells":5561},"fluorescence in situ hybridization",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5563,"activeCount":100},[],{"trials":5565,"activeCount":100},[],{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[5574],{"nctId":5575,"briefTitle":5576,"status":122,"phases":5577,"primaryCompletion":2125,"completion":168,"start":5578,"enrollment":5579,"conditions":5580,"interventions":5583},"NCT00900094","UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer",[],"2000-06",200,[15,33,161,5581,5582,4719,21],"Liver Cancer","Lung Cancer",[5560,5584,5585],"polymerase chain reaction","protein expression analysis",{"intervention":5584,"totalTrials":138,"cells":5587},{"EARLY_PHASE1":5588,"PHASE1":5590,"PHASE2":5592,"PHASE3":5594,"PHASE4":5596,"NA":5598},{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[],{"trials":5599,"activeCount":100},[5600],{"nctId":5575,"briefTitle":5576,"status":122,"phases":5601,"primaryCompletion":2125,"completion":168,"start":5578,"enrollment":5579,"conditions":5602,"interventions":5603},[],[15,33,161,5581,5582,4719,21],[5560,5584,5585],{"intervention":5585,"totalTrials":138,"cells":5605},{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5612,"PHASE4":5614,"NA":5616},{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[5618],{"nctId":5575,"briefTitle":5576,"status":122,"phases":5619,"primaryCompletion":2125,"completion":168,"start":5578,"enrollment":5579,"conditions":5620,"interventions":5621},[],[15,33,161,5581,5582,4719,21],[5560,5584,5585],{"intervention":5623,"totalTrials":138,"cells":5624},"Paclitaxel 80mg\u002Fm2 weekly x 12 weeks",{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"trials":5630,"activeCount":100},[],{"trials":5632,"activeCount":100},[],{"trials":5634,"activeCount":100},[],{"trials":5636,"activeCount":100},[5637],{"nctId":5638,"briefTitle":5639,"status":122,"phases":5640,"primaryCompletion":5641,"completion":5641,"start":5642,"enrollment":5643,"conditions":5644,"interventions":5645},"NCT02338115","Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients",[],"2016-12-20","2014-05",60,[15],[5623],{"intervention":5482,"totalTrials":138,"cells":5647},{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5652,"PHASE3":5654,"PHASE4":5656,"NA":5658},{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[5660],{"nctId":5476,"briefTitle":5477,"status":122,"phases":5661,"primaryCompletion":2237,"completion":5479,"start":4417,"enrollment":216,"conditions":5662,"interventions":5663},[],[15,5438,4286],[5454,5482,5483],{"intervention":5483,"totalTrials":138,"cells":5665},{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5672,"PHASE4":5674,"NA":5676},{"trials":5667,"activeCount":100},[],{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"trials":5673,"activeCount":100},[],{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[5678],{"nctId":5476,"briefTitle":5477,"status":122,"phases":5679,"primaryCompletion":2237,"completion":5479,"start":4417,"enrollment":216,"conditions":5680,"interventions":5681},[],[15,5438,4286],[5454,5482,5483],{"intervention":5683,"totalTrials":138,"cells":5684},"anastrozole, letrozole, exemestane",{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5693,"NA":5695},{"trials":5686,"activeCount":100},[],{"trials":5688,"activeCount":100},[],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[5697],{"nctId":5698,"briefTitle":5699,"status":122,"phases":5700,"primaryCompletion":5701,"completion":5701,"start":1089,"enrollment":5702,"conditions":5703,"interventions":5705},"NCT01896050","Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",[],"2014-08",115,[15,4286,5704],"Obesity",[5683,5706],"Tamoxifen",{"intervention":5706,"totalTrials":138,"cells":5708},{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[5721],{"nctId":5698,"briefTitle":5699,"status":122,"phases":5722,"primaryCompletion":5701,"completion":5701,"start":1089,"enrollment":5702,"conditions":5723,"interventions":5724},[],[15,4286,5704],[5683,5706]]